

Lisa Seng

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Wednesday, 3 February 2021 3:07 PM
To: Hannah Walker; Jonathan Lane; Simon Rae; Peter Crabtree
Subject: Canada is gearing up to manufacture its own Novovax. Good to think about what we are planning here.

Follow Up Flag: Follow up
Flag Status: Completed

<https://edition.cnn.com/2021/02/02/americas/canada-coronavirus-vaccines/index.html>

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director of Research

9/2(a)
E: director@malaghan.org.nz
O: <http://orcid.org/0000-0002-5721-0442>
A: PO Box 7060, Wellington 6242, New Zealand
W: www.malaghan.org.nz

M MALAGHAN
INSTITUTE
Harnessing the power
of the immune system

Lisa Seng

From: Oliver Jarvis 9(2)(a)
Sent: Wednesday, 31 March 2021 2:27 PM
To: Jonathan Lane
Cc: Fran Priddy; Hannah Walker
Subject: Clinical trial budget

Follow Up Flag: Follow up
Flag Status: Completed

Hi Jonathan,

Attached is the indicative budget for the clinical trial, broken down a few different ways. Please let me know if you have any questions. There may be some savings around the database and assay work/staff, but this is yet to be confirmed, so I've budgeted under the assumption of the more expensive option for now.

Also, did we agree the 16th, 1pm – 2pm for our next catch up?

Kind regards
Oliver

9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)



9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

Oliver Jarvis

Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Huaketo

9(2)(a)

W: www.malaghan.org.nz

A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

Lisa Seng

From: Jonathan Lane
Sent: Friday, 19 February 2021 10:42 AM
To: Oliver Jarvis
Cc: Hannah Walker; Graham LeGros
Subject: RE: Clinical Budget [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks, Oliver. I agree in principle with leaving some resources for VM for an extended period, but the devil will be in the detail. We can talk through the details once I get advice from Health on the proposed repurposing of clinical trial funds.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Oliver Jarvis 9(2)(a)
Sent: Friday, 19 February 2021 10:36 a.m.
To: Jonathan Lane
Cc: Hannah Walker; Graham LeGros
Subject: Re: Clinical Budget [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi Jonathan,

Proportions by Institute are:

Clinical Provider 9(2)(b)(i), 9(2)(b)(ii), 9(2)(j)
This includes some stuff like the clinical database 9(2)(b)(i), 9(2)(b)(ii), 9(2)(j)

MIMR 9(2)(b)(i), 9(2)(b)(ii), 9(2)(j)
This includes processing of samples/ purchase of sample kits, 9(2)(b)(i), 9(2)(b)(ii), 9(2)(j)

UoO 9(2)(b)(i), 9(2)(b)(ii), 9(2)(j)
James's time

FTE changes at the end of the main program are:

9(2)(a)

Not included in the clinical budget, but a thought I've had would also be to delay some of the Vision Mātauranga budget to publicise results of the Maori cohort, to help support Maori vaccine uptake. This is included in the current budget though, not requiring clinical funding.

Kind regards
Oliver

Oliver Jarvis
Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Huaketo

9(2)(a)
[Redacted]
[Redacted]

W: www.malaghan.org.nz
A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Jonathan Lane 9(2)(a)
Date: Thursday, 18 February 2021 at 5:02 PM
To: Oliver Jarvis 9(2)(a)
Cc: Hannah Walker 9(2)(a), Graham LeGros <glegros@malaghan.org.nz>
Subject: RE: Clinical Budget [IN-CONFIDENCE:RELEASE-EXTERNAL]

Thanks for this and the phone call, Oliver. I'd be grateful if you could also specify approximately how much funding goes to the Malaghan Institute, to the University of Otago, to clinical trial providers (and others, if any).

Can you please confirm from our phone call that:

- proposed FTE in science leadership is Fran Priddy 9(2)(a), 9(2)(b), Graham Le Gros 9(2)(a), 9(2)(b), 9(2)(c) and James Ussher 9(2)(a), 9(2)(b), 9(2)(c) (for est Nov 2021-August 2022)
- proposed FTE in Programme mgt includes 9(2)(a), 9(2)(b) of Oliver Jarvis (for the extended period – est Nov 2021-August 2022)
- costs cover observation trials of two vaccines – Pfizer and the next one to roll out.

We understand that these are estimates and that the non-contingency costs are based on the assumption that the study, 12-month monitoring and analysis will be complete by August 2022.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)
[Redacted]

15 Stout Street, Level 6
PO Box 1473, Wellington 6145

New Zealand

From: Oliver Jarvis 9(2)(a)

Sent: Thursday, 18 February 2021 4:03 p.m.

To: Jonathan Lane

Cc: Hannah Walker; Graham LeGros

Subject: Clinical Budget


Hi Jonathan,

Here is some more detail on the draft clinical budget – please let me know if you require more detail or have any questions.

Kind regards

Oliver

9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)



Oliver Jarvis

Program Manager

Vaccine Alliance Aotearoa New Zealand

Ōhū Kaupare Huaketo

9(2)(a)



W: www.malaghan.org.nz

A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Thursday, 18 February 2021 4:09 PM
To: Oliver Jarvis; Jonathan Lane
Cc: Hannah Walker
Subject: Re: Clinical Budget

Dear Jonathan and Hannah,

It could be added that most of these numbers are based on quotes or almost finished negotiated quotes. Its still draft of course but they are being carefully worked through as we speak.

So there are no surprises

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director of Research

9(2)(a)
E: director@malaghan.org.nz
O: <http://orcid.org/0000-0002-5721-0442>
A: PO Box 7060, Wellington 6242, New Zealand
W: www.malaghan.org.nz



From: Oliver Jarvis 9(2)(a)
Date: Thursday, 18 February 2021 at 4:02 PM
To: Jonathan Lane 9(2)(a)
Cc: Hannah Walker 9(2)(a), "glegros@malaghan.org.nz" <glegros@malaghan.org.nz>
Subject: Clinical Budget

Hi Jonathan,

Here is some more detail on the draft clinical budget – please let me know if you require more detail or have any questions.

Kind regards
Oliver

9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

Oliver Jarvis
Program Manager

Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Huaketo

9(2)(a)

W: www.malaghan.org.nz

A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

RELEASED UNDER
OFFICIAL INFORMATION ACT

Lisa Seng

From: Oliver Jarvis 9(2)(a)
Sent: Thursday, 1 April 2021 2:43 PM
To: Jonathan Lane
Cc: Fran Priddy; Hannah Walker
Subject: Re: Clinical trial budget [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks Jonathan,

Actually working from pfr/cawthron in Nelson today.

I've realised that the clinical producers overheads aren't broken out. They're relatively minor [REDACTED] but this can be done if needed.

Do you know what sort of timeframe we're looking at for a decision on the trial?

Kind regards
Oliver

Oliver Jarvis
Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Hukareto

9(2)(a)
[REDACTED]
[REDACTED]

W: www.malaghan.org.nz

A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Jonathan Lane 9(2)(a)
Date: Thursday, 1 April 2021 at 2:11 PM
To: Oliver Jarvis 9(2)(a)
Cc: Fran Priddy <fpriddy@malaghan.org.nz>, Hannah Walker 9(2)(a)
Subject: RE: Clinical trial budget [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks for this, Oliver, and sorry I missed your call yesterday. Good to have this level of detail. I understand you're on holiday – I hope you enjoy your Easter weekend.

Yes, the 16th, 1pm – 2pm will work for our next catch up. Thanks for the prompt.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Oliver Jarvis 9(2)(a)
Sent: Wednesday, 31 March 2021 2:27 p.m.
To: Jonathan Lane
Cc: Fran Priddy; Hannah Walker
Subject: Clinical trial budget

Hi Jonathan,

Attached is the indicative budget for the clinical trial, broken down a few different ways. Please let me know if you have any questions. 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

Also, did we agree the 16th, 1pm – 2pm for our next catch up?

Kind regards
Oliver

9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

Oliver Jarvis
Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Huaketo

9(2)(a)

A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Jonathan Lane
Sent: Wednesday, 14 April 2021 1:50 PM
To: Oliver Jarvis
Subject: RE: Clinical trial budget [IN-CONFIDENCE:RELEASE EXTERNAL]

Great, thanks for the confirmation.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hikina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Oliver Jarvis 9(2)(a)
Sent: Wednesday, 14 April 2021 1:33 p.m.
To: Jonathan Lane
Subject: Re: Clinical trial budget [IN-CONFIDENCE:RELEASE EXTERNAL]

Yep, the database quote if for approx. 9(2)(a) rather than the 9(2)(a) budgeted.

Kind regards
Oliver

Oliver Jarvis
Business Development Officer / Program Manager (VAANZ)

9(2)(a)

W: www.malaghan.org.nz
A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand
PA: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Jonathan Lane 9(2)(a)
Date: Wednesday, 14 April 2021 at 11:37 AM

To: Oliver Jarvis 9(2)(a)

Cc: Fran Priddy <fpriddy@malaghan.org.nz>, Hannah Walker 9(2)(a)

Subject: RE: Clinical trial budget [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Oliver. I had a phone call with Graham last night where he mentioned that you'd got a revised price for the database work – can you let me know what that is?

Regards

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS

Science System Investment and Performance · Labour, Science and Enterprise

Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Oliver Jarvis 9(2)(a)

Sent: Wednesday, 31 March 2021 2:27 p.m.

To: Jonathan Lane

Cc: Fran Priddy; Hannah Walker

Subject: Clinical trial budget

Hi Jonathan,

Attached is the indicative budget for the clinical trial, broken down a few different ways. Please let me know if you have any questions. There may be some savings around the database and assay work/staff, but this is yet to be confirmed, so I've budgeted under the assumption of the more expensive option for now.

Also, did we agree the 16th, 1pm – 2pm for our next catch up?

Kind regards

Oliver

9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

Oliver Jarvis
Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Huaketo

9(2)(a)

W: www.malaghan.org.nz
A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Jonathan Lane
Sent: Thursday, 1 April 2021 2:12 PM
To: Oliver Jarvis
Cc: Fran Priddy; Hannah Walker
Subject: RE: Clinical trial budget [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks for this, Oliver, and sorry I missed your call yesterday. Good to have this level of detail. I understand you're on holiday – I hope you enjoy your Easter weekend.

Yes, the 16th, 1pm – 2pm will work for our next catch up. Thanks for the prompt.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)
[REDACTED]

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Oliver Jarvis 9(2)(a)
Sent: Wednesday, 31 March 2021 2:27 p.m.
To: Jonathan Lane
Cc: Fran Priddy; Hannah Walker
Subject: Clinical trial budget


Hi Jonathan,

Attached is the indicative budget for the clinical trial, broken down a few different ways. Please let me know if you have any questions. 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)
[REDACTED]

Also, did we agree the 16th, 1pm – 2pm for our next catch up?

Kind regards
Oliver

9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)



ACT

Oliver Jarvis
Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Huaketo

9(2)(a) [redacted]
[redacted]
[redacted]

W: www.malaghan.org.nz
A: PO Box 7060, Wellington 6242, New Zealand

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Lisa Seng

From: Oliver Jarvis 9(2)(a)
Sent: Wednesday, 14 April 2021 1:33 PM
To: Jonathan Lane
Subject: Re: Clinical trial budget [IN-CONFIDENCE:RELEASE EXTERNAL]

Yep, the database quote is for approx [REDACTED], rather than the [REDACTED] budgeted.

Kind regards
Oliver

Oliver Jarvis

Business Development Officer / Program Manager (VAANZ)

9(2)(a)

W: www.malaghan.org.nz

A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand

PA: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Jonathan Lane 9(2)(a)
Date: Wednesday, 14 April 2021 at 11:37 AM
To: Oliver Jarvis 9(2)(a)
Cc: Fran Priddy <fpriddy@malaghan.org.nz>, Hannah Walker 9(2)(a)
Subject: RE: Clinical trial budget [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Oliver. I had a phone call with Graham last night where he mentioned that you'd got a revised price for the database work – can you let me know what that is?

Regards

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS

Science System Investment and Performance · Labour, Science and Enterprise

Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand


From: Oliver Jarvis 9(2)(a)
Sent: Wednesday, 31 March 2021 2:27 p.m.
To: Jonathan Lane
Cc: Fran Priddy; Hannah Walker
Subject: Clinical trial budget

Hi Jonathan,

Attached is the indicative budget for the clinical trial, broken down a few different ways. Please let me know if you have any questions. 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(f)

Also, did we agree the 16th, 1pm – 2pm for our next catch up?

Kind regards
Oliver



9(2)(ba)(i), 9(2)(b)(ii), 9(2)(f)

Oliver Jarvis

Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Huaketo

9(2)(a)

W: www.malaghan.org.nz

A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Jonathan Lane
Sent: Wednesday, 14 April 2021 5:49 PM
To: Graham Le Gros (glegros@malaghan.org.nz); James Ussher
Cc: Oliver Jarvis 9(2)(a); Hannah Walker
Subject: FINAL Feedback Letter - Progress Report and Forward-looking Plan.pdf [IN-CONFIDENCE:RELEASE EXTERNAL]
Attachments: FINAL Feedback Letter - Progress Report and Forward-looking Plan.pdf

Dear Graham, James and Oliver – please find attached a letter from Danette Olsen seeking further information on the Interim Progress Report for the SSIF Vaccine Platform/VAANZ. Please contact me or Hannah in the first instance with questions. We're out of the office tomorrow 15/4/2021 but available Friday 16/4 and we can discuss any questions at our regular meeting on Friday.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand



14 April 2021

To: Professor Graham Le Gros
glegros@malaghan.org.nz

Associate Professor James Ussher
james.ussher@otago.ac.nz

Strategic Science Investment Fund Vaccine Platform – Progress Reporting 1 August 2020 – 31 October 2021

Dear Graham, James

Thank you for submitting your Initial Progress Report and Forward-looking Plan for the Strategic Science Investment Fund (SSIF) Vaccine Platform Programmes Contract.

MBIE discussed this report with you on 11 February 2021 and is pleased with the progress the team has made in building vaccine development capability to date.

In order to fully satisfy the reporting requirements for the initial Progress Report, MBIE requires more detailed information on the areas outlined in Annex One. If this information is commercially sensitive please indicate in the report.

For the information sought in the *Funding Summary* and *Project-level information* areas in Annex One, please provide information only for the reporting period (1 August 2020 – 31 December 2020). For all the other areas in Annex One, please provide the most current information you have.

The IMS portal has been re-opened for submission of the information, please note that you may need an IMS Super User to resubmit the required information. The information is required by 30 April 2021.

If you have any questions please do not hesitate to contact your MBIE lead contact Jonathan Lane (9(2)(a)) in the first instance.

Yours sincerely

Danette Olsen
Manager Strategic Investments
Ministry of Business, Innovation and Employment



Annex One: Further Information Required

Area of Report	Information needed
Introduction Start date	Please enter 1 August 2020 in the text box in IMS
Introduction End date	Please enter 31 December 2020 in the text box in IMS
Funding Summary	<p>Please clarify SSIF expenditure for the reporting period (1 August 2020 – 31 December 2020) against:</p> <ul style="list-style-type: none"> • Project Management - \$ • Science Capability - \$ • Challenge Testing Capability - \$ • Viral Seedbank - \$ • Candidate screening - \$ <p>Spend to date should specify SSIF funding (i.e. separate from or excluding charitable etc funds).</p>
Progress and Key Achievements	<p>The initial report submitted says VAANZ is investigating "several" other pan-coronavirus vaccine candidates – please give details for what these are. 9(2)(b)(i), 9(2)(b)(ii)</p> <p>What candidates "can be updated regularly"? What opportunities are there for VAANZ with these or other candidates? What opportunities are there to deal with variants of SARS-COV-2 or possible new viruses that may present a threat to New Zealand? What options are there for VAANZ to do these investigations, what are the timeframes?</p>
Key Performance Indicators	<p>For the KPI 02.02.00 'Platform candidates regularly reviewed by vaccine advisory group' - MBIE needs to see further information in regard to the 'Documented evidence of peer review and Platform's response to recommendations'. We need to see details of the documentation of the progress so far, what has been accepted/declined and why. (If it is difficult to put this information into IMS, MBIE are happy to receive this by email).</p> <p>For KPI 03.03.00 – need more detailed information on the six external candidates that have been formally submitted to the platform and assessed. Please identify any commercially sensitive information.</p> <p>For KPI 04.02.00 – how are VAANZ working with University of Auckland?</p> <p>For KPI 07.01.00 – how are VAANZ working with the Ministry of Health (MoH) on communications with Māori on vaccines, how will the Platform complement MoH's work?</p>
Impact	<p>As with KPI 03.03.00 above, MBIE requires more information on what candidates have been selected or excluded i.e. type, research team, challenges/advantages etc. Please identify any commercially sensitive information.</p> <p>The Plan mentions the potential role of the coronavirus seedbank in countering the harms of virus mutations – please provide more detailed information on what the seedbank sub-project has achieved to date.</p>
Science Excellence	What are the mechanisms established/used to ensure that the research is excellent?
Horizons	How do rollout plans affect timelines for delivery, and do they affect the profile of the contract with regard to horizons of research?
Investing in people	Please provide more detailed information, particularly in regard to development of early career researchers.
Domestic and international collaboration	<p>More detail on collaborators is needed (outside Melbourne). What have collaborators brought to the project? 9(2)(a) - the report outlines that the collaboration has happened, but not much on what it achieved. Please state if commercially sensitive.</p>
Project-level information	Update SSIF funding to date (1 August 2020 – 31 December 2020) in line with expenditure.

Lisa Seng

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Wednesday, 17 February 2021 9:35 AM
To: Jonathan Lane; Hannah Walker; Oliver Jarvis
Subject: For those who might have missed the item on Te Ao with Moana, Maia Brewerton who is one of our VAANZ advisors is doing good work in the community around the vaccine uptake in Maori

<https://www.stuff.co.nz/pou-tiaki/300231558/mori-doctors-address-the-issue-of-vaccine-hesitancy-as-the-covid19-vaccination-is-set-to-roll-out>

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)

Director of Research

9(2)(a)

E: director@malaghan.org.nz

O: <http://orcid.org/0000-0002-5721-0442>

A: PO Box 7060, Wellington 6242, New Zealand

W: www.malaghan.org.nz



Harnessing the power
of the immune system

Lisa Seng

From: Jonathan Lane
Sent: Wednesday, 17 February 2021 8:54 PM
To: Graham LeGros; Hannah Walker; Oliver Jarvis
Subject: RE: For those who might have missed the item on Te Ao with Moana, Maia Brewerton who is one of our VAANZ advisors is doing good work in the community around the vaccine uptake in Maori [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks, Graham. Very positive messaging.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance - Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hikina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Graham LeGros [mailto:glegros@malaghan.org.nz]
Sent: Wednesday, 17 February 2021 9:35 a.m.
To: Jonathan Lane; Hannah Walker; Oliver Jarvis
Subject: For those who might have missed the item on Te Ao with Moana, Maia Brewerton who is one of our VAANZ advisors is doing good work in the community around the vaccine uptake in Maori

<https://www.stuff.co.nz/pou-tiaki/300231558/mori-doctors-address-the-issue-of-vaccine-hesitancy-as-the-covid19-vaccination-is-set-to-roll-out>

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director of Research

9(2)(a)

E: director@malaghan.org.nz
O: <http://orcid.org/0000-0002-5721-0442>
A: PO Box 7060, Wellington 6242, New Zealand
W: www.malaghan.org.nz

 **MALAGHAN**
INSTITUTE
Harnessing the power
of the immune system

Lisa Seng

From: Oliver Jarvis 9(2)(a)
Sent: Thursday, 22 April 2021 11:48 AM
To: Graham LeGros
Cc: Jonathan Lane; Bethany Andrews
Subject: FW: Letter from Hon Chris Hipkins, Minister for COVID-19 Response
Attachments: Letter from Hon Chris Hipkins.pdf

Kind regards
Oliver

Oliver Jarvis

Business Development Officer / Program Manager (VAANZ)

9(2)(a)

W: www.malaghan.org.nz

A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand

PA: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Mele Tasola 9(2)(a)
Date: Wednesday, 21 April 2021 at 5:19 PM
To: Oliver Jarvis 9(2)(a)
Subject: Letter from Hon Chris Hipkins, Minister for COVID-19 Response

Kia ora,

On behalf of Hon Chris Hipkins please see attached letter.

Kind regards,
Mele

Mele Tasola | Private Secretary (Executive Support) | Office of Hon Chris Hipkins
Minister for COVID-19 Response | Minister of Education | Minister of the Public Service | Leader of the House
Parliament Buildings, Private Bag 18041, Wellington 6160, New Zealand

Hon Chris Hipkins

MP for Remutaka

Minister for COVID-19 Response

Minister of Education

Minister for the Public Service

Leader of the House



21 April 2021

Oliver Jarvis

VAANZ

9(2)(a)

Dear Oliver Jarvis,

I know that you are well aware that the testing and vaccination of people working at New Zealand's border (including Managed Isolation and Quarantine facilities) is a critical component of New Zealand's response to COVID-19. The border is a high risk place, with the potential for workers to contact the virus and transmit it into our communities.

Regrettably, it has become apparent that testing and vaccination of border workers has not been happening as well as it should. One recent example is the case of an infected Managed Isolation and Quarantine worker who had not been regularly tested as required under the Border Testing Order.

We all need to strengthen our efforts to ensure New Zealanders are kept safe.

From 27 April 2021 the use of the Border Workers Testing Register will become compulsory under the COVID-19 Public Health Response (Required Testing) Order 2020. You will be required to ensure that information about those border workers covered by the Order is captured accurately in the register. Having a single repository of information about the status of those required to be tested will help to ensure compliance with the testing regime. You must also monitor the testing status of your workers to ensure they are complying with the Order.

Border workers have been the first group of people offered the COVID-19 vaccine in New Zealand. I expect that you have been encouraging your workers to be vaccinated. Despite this, I am aware of hesitancy to take up of the vaccine by a small number of border workers.

The Government has been clear that it wants front line border workers to be vaccinated, to protect themselves and others, and I am looking to you to lead this in your organisation. The Government will reinforce this expectation with more formal requirements in the coming days.

If you have any questions about how you can help meet the Government's expectations, please discuss them with the public service Chief Executive for your sector.

Thank you for the way in which you have been supporting the testing regime and the commitment you have shown in supporting your people to be vaccinated. Your actions are a critical part of ensuring that COVID-19 is kept out of New Zealand's communities.

Yours sincerely

Chris Hipkins

Minister for COVID-19 Response

Lisa Seng

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Thursday, 22 April 2021 12:17 PM
To: Oliver Jarvis; Mele Tasola
Cc: Bethany Andrews; Jonathan Lane
Subject: Re: Letter from Hon Chris Hipkins, Minister for COVID-19 Response

Dear Oliver,

Have you talked with Mela, I would like to do a formal response to this letter.

G

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director of Research

9(2)(a)
E: director@malaghan.org.nz
O: <http://orcid.org/0000-0002-5721-0442>
A: PO Box 7060, Wellington-6242, New Zealand
W: www.malaghan.org.nz



From: Oliver Jarvis 9(2)(a)
Date: Thursday, 22 April 2021 at 11:37 AM
To: Mele Tasola 9(2)(a)
Cc: "glegros@malaghan.org.nz" <glegros@malaghan.org.nz>, Bethany Andrews 9(2)(a), Jonathan Lane 9(2)(a)
Subject: Re: Letter from Hon Chris Hipkins, Minister for COVID-19 Response

Hi Mela, thank you for this.

A few questions:

- In the VAANZ program, there will be two sites working with live SARS-CoV-2, the University of Otago PC3 lab (currently working with the virus) and the MPI National Biocontainment Lab at Wallaceville (will soon be working with live covid). As these sites are not on the border or MIQ facilities, are they captured under the COVID-19 Public Health Response act?
- I've been working to have all staff vaccinated, and I've got the staff working at Wallaceville mostly done, just chasing down one for both doses, and waiting for second doses for a few. The staff in the University of Otago lab are currently on the Southern DHB list for vaccination, but have been put in the same class as healthcare workers, and are yet to have a date set for their vaccinations. If these staff are being considered border workers (or equivalents), are you able to help get them into that category? I've had to take what I can get from the DHB.

- Is regular testing required for staff at these locations? This is not currently being done, but could be implemented. We don't have access to the register however.

Thanks for your help – our program doesn't fit into the current categories, so am happy to get advice on how to handle this. I can arrange a call if that would be helpful.

Kind regards
Oliver

Oliver Jarvis

Business Development Officer / Program Manager (VAANZ)

9(2)(a)

W: www.malaghan.org.nz

A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand

PA: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Mele Tasola 9(2)(a)

Date: Wednesday, 21 April 2021 at 5:19 PM

To: Oliver Jarvis 9(2)(a)

Subject: Letter from Hon Chris Hipkins, Minister for COVID-19 Response

Kia ora,

On behalf of Hon Chris Hipkins please see attached letter.

Kind regards,
Mele

Mele Tasola | Private Secretary (Executive Support) | Office of Hon Chris Hipkins
Minister for COVID-19 Response | Minister of Education | Minister of the Public Service | Leader of the House
Parliament Buildings, Private Bag 18041, Wellington 6160, New Zealand

Lisa Seng

From: Hannah Walker
Sent: Wednesday, 28 April 2021 12:48 PM
To: glegros@malaghan.org.nz; James Ussher; 9(2)(a)
Cc: Hannah Walker; Jonathan Lane; Danette Olsen
Subject: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]
Attachments: Advice to SSIF Vaccine Platform VAANZ on changes in strategic direction and use of clinical trials funds.pdf; 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)
[REDACTED]
[REDACTED]
[REDACTED]

Kia ora Graham, James, Oliver

Following this morning's letter from Danette - please find below information in regard to the variation of contract MALA2001, the below summarises the actions required in preparation for the variation agreement. If you could provide a draft of the changes by 11 May 2021, we can then work through the content. As we have agreement in principle to vary the contract we are happy for you to progress the observational study.

This variation includes:

- changing the strategic direction for the SSIF Vaccine Platform from the COVID-19 Vaccine Task Force to MBIE's, Deputy Secretary, Labour Science and Enterprise.
- approval for the Platform to use some of the funds originally allocated to conducting clinical trials of Platform vaccine candidates to instead conduct observational studies of COVID-19 vaccine being rolled out in New Zealand in 2021.

Variations to terms and conditions of contract

- We are currently drafting changes in the terms and conditions of the contract (*Governance and Performance Management and Reporting Requirements*) to reflect the changes in governance and reporting discussed above, and will discuss the wording of those changes with you before we finalise the contract.

Summary of Variation Actions (MALA2001):

Schedule 1 – Summary

- Confirm the end date. Based on our previous discussions, we understand the end date, accounting for the observational study and analysis, to be 31 August 2022. Please discuss with us if this date has changed as a result of your revision of the project.
- Please provide details of the new Contract Manager to replace Oliver Jarvis in the IMS system.

Schedule 2 – Platform Plan

A clean document is attached 'Variation - VAANZ Vaccine Platform Contract - Platform Plan' to update. Please provide a word tracked version of the updated Platform Plan – areas that need to be amended are highlighted including:

- *Public Statement and Executive Summary* (also in Schedule 1) to update with observational study information
- Removal of reference to 'the task force' and replace with 'the Deputy Secretary, Labour, Science and Enterprise, MBIE' (this change will also be reflected in the master contract Clause 5)
- Update the information in regard to clinical trials to cover the *new observational study*
- *Budget Section* – a new document has been provided to update for the budget section (Variation - VAANZ SSIF Vaccine Platform Contract Budget), please update this document. Ensure the budget covers the entire period of the contract (i.e. to the revised end date). For the variation document we require the full budget to be entered as a word document table, please do not attach as an image. Other images have been added from the Platform Plan into the Budget document and need updated to reflect the new work

programme. 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

- Activity Description & Indicative Timeline – update for the observational study, please include a tracked word table (instead of an image).
- The Platform Plan has two appendices currently (Appendix One: Vaccine candidates, adjuvants, and preclinical assessment of immunogenicity, efficacy, and safety, Appendix Two: Coronavirus Vaccine Seedbank) – please append the observational study proposal as reviewed by Ministry of Health to the Platform Plan.

Schedule 3 - Key Performance Indicators

A clean document is attached 'Variation - VAANZ SSIF Vaccine Platform Contract KPIs' to update. Please provide a word tracked version of the KPI document attached – areas that need amended are highlighted including:

- Removal of reference to 'the task force' and replace with 'the Deputy Secretary, Labour, Science and Enterprise, MBIE'
- Removal of the original 'Horizon' KPI and replace with new Horizon KPI/s for the observational study.
- Proceed on the basis that originally contracted KPIs will need to be achieved by the original contract end date, unless we are satisfied of the rationale for change.

Schedule 4 – Budget

- We will update this section with the updated information provided in the Platform Plan.

Schedule 5 - Performance management

- Final report 30/11/2011 – will be replaced by a Progress Report due on the same date (guidelines will be provided)
- A Final report will be added due September 2022
- This will be reflected in the master contract document (Clause 4.10)

Schedule 6 - Intellectual property management plan

- Please take a look at your attached IP Management Plan (Variation - VAANZ Vaccine Platform Contract - IP Management Plan) and see if this needs amended to include the observational study.

If you have any questions at all, please don't hesitate to give me a call on 9(2)(a) – Jonathan is back in the office on Monday 3rd – but I am available if you have any questions about the changes.

Ngā mihi

Hannah

Hannah Walker

(She/her)

SENIOR INVESTMENT MANAGER

Strategic Investments

Science System Investment and Performance | Labour Science and Enterprise

Ministry of Business, Innovation & Employment | Te Manatū Pakihi, Auahatanga me Ngā Kaupapa ā-Mahi

7.2 attachments have been redacted under: 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)



28 April 2021

To: Professor Graham Le Gros
glegros@malaghan.org.nz

Professor Richard Blaikie
richard.blaikie@otago.ac.nz

Associate Professor James Ussher
james.usscher@otago.ac.nz

Dr Frances Priddy
fpriddy@malaghan.org.nz

C.c: Oliver Jarvis
9(2)(a)

Strategic Science Investment Fund Vaccine Platform – Decision on use of clinical trials funds and changes in source of strategic direction

Dear Graham, James, Frances and Richard

This letter is formal advice that:

- MBIE approves your proposal to repurpose some of the funds allocated to clinical trials in the Strategic Science Investment Fund (SSIF) Vaccine Platform contract to undertake observational studies of COVID-19 vaccine safety and immune responses in New Zealand populations during the 2021 vaccination campaign
- strategic direction from government for the SSIF Vaccine Platform will change from the COVID-19 Vaccine Task Force to the Deputy Secretary, Labour, Science and Enterprise, MBIE
- MBIE will negotiate a contract variation with the Malaghan Institute to reflect the above changes.

Observational study

Thank you for the proposal to conduct an observational study of COVID-19 vaccine safety and immune responses in New Zealand populations during the 2021 vaccination campaign, focusing on the Pfizer/BioNTech vaccine in two locations. Thanks in particular to Dr Priddy for working with the Ministry of Health and their advisors in developing and refining the proposal. The Ministry of Health have advised that they support the proposed observational study. MBIE approves the repurposing of funds in the original contract for this study.

We consider that pursuing the studies will result in more effective use of SSIF funds than the current clinical trial funding, and if successfully implemented should produce:

- valuable research outcomes that can contribute to global research efforts on vaccine development and vaccination
- results that may be valuable to the rollout of vaccines in New Zealand
- an increase in vaccine clinical trial capability in New Zealand.

Thank you for the additional financial information Oliver Jarvis provided on the costs of the observational study in April 2021. We are broadly comfortable with the costs provided and will discuss their impact on the SSIF Vaccine Platform's overall budget with the Malaghan Institute during contract negotiations.

Change in strategic direction from government for the SSIF Vaccine Platform

The existing contract between MBIE and the Malaghan Institute for the SSIF Vaccine Platform specifies that the Platform would take strategic direction from the whole-of-government COVID-19 Vaccine Task Force, established as part of the COVID-19 Vaccine Strategy. The Vaccine Task Force was disestablished in early 2021. MBIE retains responsibility for the SSIF Vaccine Platform and vaccine manufacturing work. MBIE's Deputy Secretary, Labour, Science and Enterprise will provide strategic direction to the SSIF Vaccine Platform on behalf of the New Zealand Government. MBIE will continue to seek advice from the Ministry of Health and its advisors in relation to the Platform's strategic direction where needed.

Contract variation

MBIE will formalise the changes above in a contract variation negotiated with the Malaghan Institute as contract holder. Hannah Walker is leading work on the variation and will contact the Malaghan Institute separately.

Thank you for the work you have conducted to date and for your work in ensuring that the SSIF Vaccine Platform remains relevant in the face of a rapidly-changing global and New Zealand environment.

If you have any further questions, including comments on the timeline and process above, please do not hesitate to contact your MBIE lead contact Jonathan Lane 9(2)(a) in the first instance.

Yours sincerely



Danette Olsen
Manager Strategic Investments
Ministry of Business, Innovation and Employment

Lisa Seng

From: Jonathan Lane
Sent: Tuesday, 29 June 2021 2:33 PM
To: Bethany Andrews (bandrews@malaghan.org.nz)
Cc: Neil Dalphin
Subject: FW: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]
Attachments: Advice to SSIF Vaccine Platform VAANZ on changes in strategic direction and use of clinical trials funds.pdf; 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(f)

Hi, Bethany. Wondering how you're going on getting the information for the variation together and what your ETA is for getting it to MBIE. Happy to discuss if anything is unclear.

Regards

Jonathan Lane (he/him)
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Hannah Walker 9(2)(a)
Sent: Wednesday, 28 April 2021 12:48 pm
To: glegros@malaghan.org.nz; James Ussher <james.ussheer@otago.ac.nz>; 9(2)(a)
Cc: Hannah Walker 9(2)(a); Jonathan Lane 9(2)(a); Danette Olsen <Danette.Olsen@mbie.govt.nz>
Subject: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]

Kia ora Graham, James, Oliver

Following this morning's letter from Danette - please find below information in regard to the variation of contract MALA2001, the below summarises the actions required in preparation for the variation agreement. If you could provide a draft of the changes by 11 May 2021, we can then work through the content. As we have agreement in principle to vary the contract we are happy for you to progress the observational study.

This variation includes:

- changing the strategic direction for the SSIF Vaccine Platform from the COVID-19 Vaccine Task Force to MBIE's, Deputy Secretary, Labour Science and Enterprise.
- approval for the Platform to use some of the funds originally allocated to conducting clinical trials of Platform vaccine candidates to instead conduct observational studies of COVID-19 vaccine being rolled out in New Zealand in 2021.

Variations to terms and conditions of contract

- We are currently drafting changes in the terms and conditions of the contract (*Governance and Performance Management and Reporting Requirements*) to reflect the changes in governance and reporting discussed above, and will discuss the wording of those changes with you before we finalise the contract.

Summary of Variation Actions (MALA2001):

Schedule 1 – Summary

- Confirm the end date. Based on our previous discussions, we understand the end date, accounting for the observational study and analysis, to be 31 August 2022. Please discuss with us if this date has changed as a result of your revision of the project.
- Please provide details of the new Contract Manager to replace Oliver Jarvis in the IMS system.

Schedule 2 – Platform Plan

A clean document is attached 'Variation - VAANZ Vaccine Platform Contract - Platform Plan' to update. Please provide a word tracked version of the updated Platform Plan – areas that need to be amended are highlighted including:

- *Public Statement and Executive Summary* (also in Schedule 1) to update with observational study information
- Removal of reference to 'the task force' and replace with 'the Deputy Secretary, Labour, Science and Enterprise, MBIE' (this change will also be reflected in the master contract Clause 5)
- Update the information in regard to clinical trials to cover the *new observational study*
- *Budget Section* – a new document has been provided to update for the budget section (Variation - VAANZ SSIF Vaccine Platform Contract Budget), please update this document. Ensure the budget covers the entire period of the contract (i.e. to the revised end date). For the variation document we require the full budget to be entered as a word document table, please do not attach as an image. Other images have been added from the Platform Plan into the Budget document and need updated to reflect the new work programme. 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)
- *Activity Description & Indicative Timeline* – update for the observational study, please include a tracked word table (instead of an image).
- The Platform Plan has two appendices currently (Appendix One: Vaccine candidates, adjuvants, and preclinical assessment of immunogenicity, efficacy, and safety, Appendix Two: Coronavirus Vaccine Seedbank) – please append the observational study proposal as reviewed by Ministry of Health to the Platform Plan.

Schedule 3 - Key Performance Indicators

A clean document is attached 'Variation - VAANZ SSIF Vaccine Platform Contract KPIs' to update. Please provide a word tracked version of the KPI document attached – areas that need amended are highlighted including:

- Removal of reference to 'the task force' and replace with 'the Deputy Secretary, Labour, Science and Enterprise, MBIE'
- Removal of the original 'Horizon' KPI and replace with new Horizon KPI/s for the observational study.
- Proceed on the basis that originally contracted KPIs will need to be achieved by the original contract end date, unless we are satisfied of the rationale for change.

Schedule 4 – Budget

- We will update this section with the updated information provided in the Platform Plan.

Schedule 5 - Performance management

- Final report 30/11/2011 – will be replaced by a Progress Report due on the same date (guidelines will be provided)
- A Final report will be added due September 2022
- This will be reflected in the master contract document (Clause 4.10)

Schedule 6 - Intellectual property management plan

- Please take a look at your attached IP Management Plan (Variation - VAANZ Vaccine Platform Contract - IP Management Plan) and see if this needs amended to include the observational study.

If you have any questions at all, please don't hesitate to give me a call on 9(2)(a) – Jonathan is back in the office on Monday 3rd – but I am available if you have any questions about the changes.

Ngā mihi

Hannah

Hannah Walker

(She/her)

SENIOR INVESTMENT MANAGER

Strategic Investments

Science System Investment and Performance | Labour Science and Enterprise

Ministry of Business, Innovation & Employment | Te Manatū Pakihi, Auahatanga me Ngā Kaupapa ā-Mahi

7.2 attachments have been redacted under: 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)



Lisa Seng

From: Bethany Andrews <bandrews@malaghan.org.nz>
Sent: Monday, 31 May 2021 10:05 AM
To: Jonathan Lane
Cc: Hannah Walker
Subject: Re: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi Jonathan,

It was great to meet you and Hannah too. It would be beneficial to go through the contract variation and I'd like to ask that Graham is included in this meeting.

I'm afraid I'm on leave on Friday this week. Would we be able to defer this to next week? Graham and I are free at the following times:

- Wednesday 9 June: 1-2pm
- Friday 11 June: 2:30-5pm

Kind regards,
Bethany

Bethany Andrews

GMP Manager / VAANZ Programme Manager

9(2)(a)

E: bandrews@malaghan.org.nz

W: www.malaghan.org.nz

A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Jonathan Lane 9(2)(a)
Date: Friday, 28 May 2021 at 1:47 PM
To: Bethany Andrews <bandrews@malaghan.org.nz>
Cc: Hannah Walker 9(2)(a)
Subject: FW: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Bethany. Great to meet you last week. Following on from Hannah's email below and the attached material, Hannah and I would be keen to catch up on the actions needed from VAANZ to progress the contract variation. Wondering if you are available next week – the times below would work for us – any of those slots work for you?:

- next Monday 31 May 4-5pm
- next Friday 4 June before 12.30pm
- next Friday 4 June 2.30-3.30pm.

We can come up to the Malaghan.

Regards

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Hannah Walker
Sent: Wednesday, 28 April 2021 12:48 p.m.
To: glegros@malaghan.org.nz; James Ussher; 9(2)(a)
Cc: Hannah Walker; Jonathan Lane; Danette Olsen
Subject: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE-EXTERNAL]

Kia ora Graham, James, Oliver

Following this morning's letter from Danette - please find below information in regard to the variation of contract MALA2001, the below summarises the actions required in preparation for the variation agreement. If you could provide a draft of the changes by 11 May 2021, we can then work through the content. As we have agreement in principle to vary the contract we are happy for you to progress the observational study.

This variation includes:

- changing the strategic direction for the SSIF Vaccine Platform from the COVID-19 Vaccine Task Force to MBIE's, Deputy Secretary, Labour Science and Enterprise.
- approval for the Platform to use some of the funds originally allocated to conducting clinical trials of Platform vaccine candidates to instead conduct observational studies of COVID-19 vaccine being rolled out in New Zealand in 2021.

Variations to terms and conditions of contract

- We are currently drafting changes in the terms and conditions of the contract (*Governance and Performance Management and Reporting Requirements*) to reflect the changes in governance and reporting discussed above, and will discuss the wording of those changes with you before we finalise the contract.

Summary of Variation Actions (MALA2001):

Schedule 1 – Summary

- Confirm the end date. Based on our previous discussions, we understand the end date, accounting for the observational study and analysis, to be 31 August 2022. Please discuss with us if this date has changed as a result of your revision of the project.
- Please provide details of the new Contract Manager to replace Oliver Jarvis in the IMS system.

Schedule 2 – Platform Plan

A clean document is attached 'Variation - VAANZ Vaccine Platform Contract - Platform Plan' to update. Please provide a word tracked version of the updated Platform Plan – areas that need to be amended are highlighted including:

- *Public Statement and Executive Summary* (also in Schedule 1) to update with observational study information
- Removal of reference to 'the task force' and replace with 'the Deputy Secretary, Labour, Science and Enterprise, MBIE' (this change will also be reflected in the master contract Clause 5)
- Update the information in regard to clinical trials to cover the *new observational study*
- *Budget Section* – a new document has been provided to update for the budget section (Variation - VAANZ SSIF Vaccine Platform Contract Budget), please update this document. Ensure the budget covers the entire period of the contract (i.e. to the revised end date). For the variation document we require the full budget to be entered as a word document table, please do not attach as an image. Other images have been added from the Platform Plan into the Budget document and need updated to reflect the new work

programme. 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

- Activity Description & Indicative Timeline – update for the observational study, please include a tracked word table (instead of an image).
- The Platform Plan has two appendices currently (Appendix One: Vaccine candidates, adjuvants, and preclinical assessment of immunogenicity, efficacy, and safety, Appendix Two: Coronavirus Vaccine Seedbank) – please append the observational study proposal as reviewed by Ministry of Health to the Platform Plan.

Schedule 3 - Key Performance Indicators

A clean document is attached 'Variation - VAANZ SSIF Vaccine Platform Contract KPIs' to update. Please provide a word tracked version of the KPI document attached – areas that need amended are highlighted including:

- Removal of reference to 'the task force' and replace with 'the Deputy Secretary, Labour, Science and Enterprise, MBIE'
- Removal of the original 'Horizon' KPI and replace with new Horizon KPI/s for the observational study.
- Proceed on the basis that originally contracted KPIs will need to be achieved by the original contract end date, unless we are satisfied of the rationale for change.

Schedule 4 – Budget

- We will update this section with the updated information provided in the Platform Plan.

Schedule 5 - Performance management

- Final report 30/11/2011 – will be replaced by a Progress Report due on the same date (guidelines will be provided)
- A Final report will be added due September 2022
- This will be reflected in the master contract document (Clause 4.10)

Schedule 6 - Intellectual property management plan

- Please take a look at your attached IP Management Plan (Variation - VAANZ Vaccine Platform Contract - IP Management Plan) and see if this needs amended to include the observational study.

If you have any questions at all, please don't hesitate to give me a call on 9(2)(a) – Jonathan is back in the office on Monday 3rd – but I am available if you have any questions about the changes.

Ngā mihi

Hannah

Hannah Walker

(She/her)

SENIOR INVESTMENT MANAGER

Strategic Investments

Science System Investment and Performance | Labour Science and Enterprise

Ministry of Business, Innovation & Employment | Te Manatū Pakihi, Auahatanga me Ngā Kaupapa ā-Mahi

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Jonathan Lane
Sent: Friday, 16 July 2021 4:15 PM
To: Graham LeGros; bandrews@malaghan.org.nz
Cc: Neil Dalphin
Subject: RE: MALA2001 - Variation Actions [IN-CONFIDENCE:] [IN-CONFIDENCE: RELEASE-EXTERNAL]

Thanks, Graham and Bethany. Acknowledging receipt. Happy to set up a time to discuss the financials once we've had a chance to go through them.
Have a great weekend!

Regards

Jonathan Lane (he/him)
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Friday, 16 July 2021 4:00 pm
To: Jonathan Lane 9(2)(a); Neil Dalphin 9(2)(a)
Subject: FW: MALA2001 - Variation Actions [IN-CONFIDENCE:]

Dear Jonathan,

Please find attached the tracked changes versions of the variation documents to be sent to Jonathan Lane at MBIE. Please also request to meet with Jonathan to discuss financials.

- Platform Plan
- IP Management Plan (no changes)
- KPIs

Anything more please let me know.

Regards

Graham

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director (Chief Executive)

9(2)(a)
E: director@malaghan.org.nz
O: <http://orcid.org/0000-0002-5721-0442>
A: PO Box 7060, Wellington 6242, New Zealand

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Lisa Seng

From: Jonathan Lane
Sent: Monday, 31 May 2021 12:31 PM
To: Bethany Andrews
Cc: Hannah Walker
Subject: RE: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks, Bethany. Wednesday 9 June: 1-2pm works best for us. We'll come to Malaghan – can you please send us a Calendar invite?

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Bethany Andrews [mailto:bandrews@malaghan.org.nz]
Sent: Monday, 31 May 2021 10:05 a.m.
To: Jonathan Lane
Cc: Hannah Walker
Subject: Re: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi Jonathan,

It was great to meet you and Hannah too. It would be beneficial to go through the contract variation and I'd like to ask that Graham is included in this meeting.

I'm afraid I'm on leave on Friday this week. Would we be able to defer this to next week? Graham and I are free at the following times:

- Wednesday 9 June: 1-2pm
- Friday 11 June: 2:30-5pm

Kind regards,
Bethany

Bethany Andrews
GMP Manager / VAANZ Programme Manager

9(2)(a)

E: bandrews@malaghan.org.nz
W: www.malaghan.org.nz
A: PO Box 7060, Wellington 6242, New Zealand

From: Jonathan Lane 9(2)(a)
Date: Friday, 28 May 2021 at 1:47 PM
To: Bethany Andrews <bandrews@malaghan.org.nz>
Cc: Hannah Walker 9(2)(a)
Subject: FW: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Bethany. Great to meet you last week. Following on from Hannah's email below and the attached material, Hannah and I would be keen to catch up on the actions needed from VAANZ to progress the contract variation. Wondering if you are available next week – the times below would work for us – any of those slots work for you?:

- next Monday 31 May 4-5pm
- next Friday 4 June before 12.30pm
- next Friday 4 June 2.30-3.30pm.

We can come up to the Malaghan.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Hannah Walker
Sent: Wednesday, 28 April 2021 12:48 p.m.
To: glegros@malaghan.org.nz; James Ussher; 9(2)(a)
Cc: Hannah Walker; Jonathan Lane; Danette Olsen
Subject: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]

Kia ora Graham, James, Oliver

Following this morning's letter from Danette - please find below information in regard to the variation of contract MALA2001, the below summarises the actions required in preparation for the variation agreement. If you could provide a draft of the changes by 11 May 2021, we can then work through the content. As we have agreement in principle to vary the contract we are happy for you to progress the observational study.

This variation includes:

- changing the strategic direction for the SSIF Vaccine Platform from the COVID-19 Vaccine Task Force to MBIE's, Deputy Secretary, Labour Science and Enterprise.
- approval for the Platform to use some of the funds originally allocated to conducting clinical trials of Platform vaccine candidates to instead conduct observational studies of COVID-19 vaccine being rolled out in New Zealand in 2021.

Variations to terms and conditions of contract

- We are currently drafting changes in the terms and conditions of the contract (*Governance and Performance Management and Reporting Requirements*) to reflect the changes in governance and reporting discussed above, and will discuss the wording of those changes with you before we finalise the contract.

Summary of Variation Actions (MALA2001):

Schedule 1 – Summary

- Confirm the end date. Based on our previous discussions, we understand the end date, accounting for the observational study and analysis, to be 31 August 2022. Please discuss with us if this date has changed as a result of your revision of the project.
- Please provide details of the new Contract Manager to replace Oliver Jarvis in the IMS system.

Schedule 2 – Platform Plan

A clean document is attached 'Variation - VAANZ Vaccine Platform Contract - Platform Plan' to update. Please provide a word tracked version of the updated Platform Plan – areas that need to be amended are highlighted including:

- *Public Statement and Executive Summary* (also in Schedule 1) to update with observational study information
- Removal of reference to 'the task force' and replace with 'the Deputy Secretary, Labour, Science and Enterprise, MBIE' (this change will also be reflected in the master contract Clause 5)
- Update the information in regard to clinical trials to cover the *new observational study*
- *Budget Section* – a new document has been provided to update for the budget section (Variation - VAANZ SSIF Vaccine Platform Contract Budget), please update this document. Ensure the budget covers the entire period of the contract (i.e. to the revised end date). For the variation document we require the full budget to be entered as a word document table, please do not attach as an image. Other images have been added from the Platform Plan into the Budget document and need updated to reflect the new work programme. 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)
- Activity Description & Indicative Timeline – update for the observational study, please include a tracked word table (instead of an image).
- The Platform Plan has two appendices currently (Appendix One: Vaccine candidates, adjuvants, and preclinical assessment of immunogenicity, efficacy, and safety, Appendix Two: Coronavirus Vaccine Seedbank) – please append the observational study proposal as reviewed by Ministry of Health to the Platform Plan.

Schedule 3 - Key Performance Indicators

A clean document is attached 'Variation - VAANZ SSIF Vaccine Platform Contract KPIs' to update. Please provide a word tracked version of the KPI document attached – areas that need amended are highlighted including:

- Removal of reference to 'the task force' and replace with 'the Deputy Secretary, Labour, Science and Enterprise, MBIE'
- Removal of the original 'Horizon' KPI and replace with new Horizon KPI/s for the observational study.
- Proceed on the basis that originally contracted KPIs will need to be achieved by the original contract end date, unless we are satisfied of the rationale for change.

Schedule 4 – Budget

- We will update this section with the updated information provided in the Platform Plan.

Schedule 5 - Performance management

- Final report 30/11/2011 – will be replaced by a Progress Report due on the same date (guidelines will be provided)
- A Final report will be added due September 2022
- This will be reflected in the master contract document (Clause 4.10)

Schedule 6 - Intellectual property management plan

- Please take a look at your attached IP Management Plan (Variation - VAANZ Vaccine Platform Contract - IP Management Plan) and see if this needs amended to include the observational study.

If you have any questions at all, please don't hesitate to give me a call on 9(2)(a) – Jonathan is back in the office on Monday 3rd – but I am available if you have any questions about the changes.

Ngā mihi
Hannah

Hannah Walker

(She/her)

SENIOR INVESTMENT MANAGER

Strategic Investments

Science System Investment and Performance | Labour Science and Enterprise

Ministry of Business, Innovation & Employment | Te Manatū Pakihi, Auahatanga me Ngā Kaupapa ā-Mahi

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Jonathan Lane
Sent: Thursday, 1 July 2021 1:31 PM
To: Bethany Andrews
Cc: Neil Dalphin
Subject: RE: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL] [IN-CONFIDENCE: RELEASE-EXTERNAL]

Thanks for the update, Bethany. Happy for it to be properly considered by VAANZ before you send it to MBIE. If you have any questions, please contact us.

Regards

Jonathan Lane (he/him)
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance - Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hikina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Bethany Andrews <bandrews@malaghan.org.nz>
Sent: Thursday, 1 July 2021 9:10 am
To: Jonathan Lane 9(2)(a)
Cc: Neil Dalphin 9(2)(a)
Subject: Re: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi Jonathan,

I have completed drafts, including the revised budget. I am planning to go through these and seek approval to send to MBIE at our Strategy meeting. This meeting was originally scheduled for today but we pushed out to 8 July following the covid scare in Wellington. I expect to be able to send the variation over on 12 July. If you require the variation earlier than this please let me know and I will seek approval from Graham.

Kind regards,
Bethany

From: Jonathan Lane 9(2)(a)
Date: Tuesday, 29 June 2021 at 2:34 PM
To: Bethany Andrews <bandrews@malaghan.org.nz>
Cc: Neil Dalphin 9(2)(a)
Subject: FW: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Bethany. Wondering how you're going on getting the information for the variation together and what your ETA is for getting it to MBIE. Happy to discuss if anything is unclear.

Regards

Jonathan Lane (he/him)

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance - Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Hannah Walker 9(2)(a)
Sent: Wednesday, 28 April 2021 12:48 pm
To: glegros@malaghan.org.nz; James Ussher <james.usshe@otago.ac.nz>; 9(2)(a)
Cc: Hannah Walker 9(2)(a); Jonathan Lane 9(2)(a); Danette Olsen <Danette.Olsen@mbie.govt.nz>
Subject: MALA2001 - Variation Actions [IN-CONFIDENCE:RELEASE EXTERNAL]

Kia ora Graham, James, Oliver

Following this morning's letter from Danette - please find below information in regard to the variation of contract MALA2001, the below summarises the actions required in preparation for the variation agreement. If you could provide a draft of the changes by 11 May 2021, we can then work through the content. As we have agreement in principle to vary the contract we are happy for you to progress the observational study.

This variation includes:

- changing the strategic direction for the SSIF Vaccine Platform from the COVID-19 Vaccine Task Force to MBIE's, Deputy Secretary, Labour Science and Enterprise.
- approval for the Platform to use some of the funds originally allocated to conducting clinical trials of Platform vaccine candidates to instead conduct observational studies of COVID-19 vaccine being rolled out in New Zealand in 2021.

Variations to terms and conditions of contract

- We are currently drafting changes in the terms and conditions of the contract (*Governance and Performance Management and Reporting Requirements*) to reflect the changes in governance and reporting discussed above, and will discuss the wording of those changes with you before we finalise the contract.

Summary of Variation Actions (MALA2001):

Schedule 1 – Summary

- Confirm the end date. Based on our previous discussions, we understand the end date, accounting for the observational study and analysis, to be 31 August 2022. Please discuss with us if this date has changed as a result of your revision of the project.
- Please provide details of the new Contract Manager to replace Oliver Jarvis in the IMS system.

Schedule 2 – Platform Plan

A clean document is attached 'Variation - VAANZ Vaccine Platform Contract - Platform Plan' to update. Please provide a word tracked version of the updated Platform Plan – areas that need to be amended are highlighted including:

- *Public Statement and Executive Summary* (also in Schedule 1) to update with observational study information
- Removal of reference to 'the task force' and replace with 'the Deputy Secretary, Labour, Science and Enterprise, MBIE' (this change will also be reflected in the master contract Clause 5)
- Update the information in regard to clinical trials to cover the *new observational study*
- *Budget Section* – a new document has been provided to update for the budget section (Variation - VAANZ SSIF Vaccine Platform Contract Budget), please update this document. Ensure the budget covers the entire

period of the contract (i.e. to the revised end date). For the variation document we require the full budget to be entered as a word document table, please do not attach as an image. Other images have been added from the Platform Plan into the Budget document and need updated to reflect the new work programme. 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(i)

- Activity Description & Indicative Timeline – update for the observational study, please include a tracked word table (instead of an image).
- The Platform Plan has two appendices currently (Appendix One: Vaccine candidates, adjuvants, and preclinical assessment of immunogenicity, efficacy, and safety, Appendix Two: Coronavirus Vaccine Seedbank) – please append the observational study proposal as reviewed by Ministry of Health to the Platform Plan.

Schedule 3 - Key Performance Indicators

A clean document is attached 'Variation - VAANZ SSIF Vaccine Platform Contract KPIs' to update. Please provide a word tracked version of the KPI document attached – areas that need amended are highlighted including:

- Removal of reference to 'the task force' and replace with 'the Deputy Secretary, Labour, Science and Enterprise, MBIE'
- Removal of the original 'Horizon' KPI and replace with new Horizon KPI/s for the observational study.
- Proceed on the basis that originally contracted KPIs will need to be achieved by the original contract end date, unless we are satisfied of the rationale for change.

Schedule 4 – Budget

- We will update this section with the updated information provided in the Platform Plan.

Schedule 5 - Performance management

- Final report 30/11/2011 – will be replaced by a Progress Report due on the same date (guidelines will be provided)
- A Final report will be added due September 2022
- This will be reflected in the master contract document (Clause 4.10)

Schedule 6 - Intellectual property management plan

- Please take a look at your attached IP Management Plan (Variation - VAANZ Vaccine Platform Contract - IP Management Plan) and see if this needs amended to include the observational study.

If you have any questions at all, please don't hesitate to give me a call on 9(2)(a) – Jonathan is back in the office on Monday 3rd – but I am available if you have any questions about the changes.

Ngā mihi
Hannah

Hannah Walker

(She/her)

SENIOR INVESTMENT MANAGER

Strategic Investments

Science System Investment and Performance | Labour Science and Enterprise

Ministry of Business, Innovation & Employment | Te Manatū Pakihi, Auahatanga me Ngā Kaupapa ā-Mahi

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be

advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Lisa Seng

From: Fran Priddy <fpriddy@malaghan.org.nz>
Sent: Wednesday, 24 February 2021 10:57 AM
To: Jonathan Lane
Cc: Hannah Walker; Oliver Jarvis
Subject: Fw: Supporting papers for CV TAG needed.
Attachments: COVID-19 Vaccines Confirmatory Study_CV TAG.docx

Hi Jonathan - Here is the briefing paper that MOH COVID vaccine TAG reviewed prior to the meeting on Friday.
Thanks,
Fran

Frances Priddy MD MPH FACP

Clinical Director
Vaccine Alliance Aotearoa New Zealand (VAANZ)
Ohu Kaupare Huaketo

9(2)(a)
E: fpriddy@malaghan.org.nz
W: www.malaghan.org.nz
A: PO Box 7060,
Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Janelle Duncan 9(2)(a)
Sent: Thursday, February 18, 2021 12:31 PM
To: Chris Hedlund 9(2)(a)
Cc: Fran Priddy <fpriddy@malaghan.org.nz>; Tim Hanlon 9(2)(a)
Subject: RE: Supporting papers for CV TAG needed.

Hi Chris,

Please find attached paper for post—event.

Best wishes,

Janelle

From: Tim Hanlon 9(2)(a)
Sent: Thursday, 18 February 2021 11:34 am
To: Chris Hedlund 9(2)(a)
Cc: Fran Priddy <fpriddy@malaghan.org.nz>; Janelle Duncan 9(2)(a)
Subject: RE: Supporting papers for CV TAG needed.

Hi Chris,

Janelle will be in touch with papers for tomorrow and to check on arrangements.

Thank you.

Best wishes,

Tim

Dr Tim Hanlon

Post Event Pillar Lead | COVID-19 Vaccine and Immunisation Programme
Manatū Hauora | Ministry of Health

9(2)(a) | www.health.govt.nz



From: Chris Hedlund 9(2)(a)
Sent: Thursday, 18 February 2021 10:23 am
To: Pippa Scott 9(2)(a); Tim Hanlon 9(2)(a); friddy@malaghan.org.nz; Helen Petousis-Harris 9(2)(a)
Cc: Chriselle Braganza 9(2)(a)
Subject: Supporting papers for CV-TAG needed.

Please see below proposed agenda for CV TAG tomorrow and let me know if there are supporting papers for the items you will be leading. Agenda and supporting papers should be sent out by 1pm today, so your prompt action would be highly appreciated.

1. Welcome and apologies
2. Introductions
3. Overview of Immunisation Roll Out
4. Science updates – Pippa Scott
5. Vaccines for children – Pippa Scott
6. Pillar 7 activities – Tim Hanlon
 - Adverse Event Committee
 - Research projects - Fran Priddy
7. Baseline survey of Adverse Events – Helen Petousis-Harris
8. Next steps/Decisions Pending

Thank you,

Chris Hedlund | Coordinator | [She/Her](#)
Science & Technical Advisory | Rōpū tohutohu i te pūtaiao me te hangarau
COVID-19 Health System Response | Ministry of Health - Manatū Hauora | New Zealand

Statement of confidentiality: This e-mail message and any accompanying attachments may contain information that is IN-CONFIDENCE and subject to legal privilege.

If you are not the intended recipient, do not read, use, disseminate, distribute or copy this message or attachments.

If you have received this message in error, please notify the sender immediately and delete this message.

This e-mail message has been scanned for Viruses and Content and cleared by the Ministry of Health's Content and Virus Filtering Gateway

Memo

COVID-19 Vaccines Safety and Immunogenicity Study

Date:	18 February 2021
To:	COVID-19 Vaccine Technical Advisory Group
From:	Dr Tim Hanlon, Post Event Pillar Lead, COVID-19 Vaccine and Immunisation Programme
For your:	Decision

Purpose of report

This memo seeks for you to approve in principal for the Ministry of Health to endorse The Vaccine Alliance Aotearoa New Zealand - Ohu Kaupare Huaketo (VAANZ) in their proposed observational study to evaluate the safety and immunogenicity of COVID-19 vaccines in adults in New Zealand. VAANZ have requested the Ministry's collaboration to contact the vaccine developers and to facilitate trial sites.

Background and context

1. The NZ COVID-19 Vaccine Strategy includes the purchase of at least four COVID-19 vaccines and a sequenced vaccination campaign prioritized to different population groups.
2. The four vaccines have demonstrated efficacy and short-term safety in pivotal clinical trials. However, no COVID-19 vaccines have been trialled in New Zealand, and the pivotal trials to date enrolled a minimal number of Pacific populations.
3. Although it is expected that these vaccines will behave in a similar manner in different ethnic populations; it is important during widespread campaigns with new vaccines to monitor early data on the safety and immune response in local populations, to enhance vaccine confidence and to inform public communications and safety surveillance.
4. VAANZ propose to conduct an observational study to support the implementation of COVID-19 vaccines for the New Zealand population. The study will assess safety, reactogenicity and immunogenicity in a subset of vaccine recipients during the initial roll-out of each vaccine.
5. A single protocol has been developed that can be adapted to reflect timeframes and assays indicated for specific vaccines. The study will enrol a cohort of at least 250 adult vaccine recipients for each vaccine; additional cohorts may be enrolled to ensure adequate evaluation of Māori, Pasifika and adults ≥ 65 years of age. [Study protocol attached as Appendix 1]
6. Samples from participants will be bio-banked which will be important for future research objectives such as vaccine responses to variant viruses in vitro, performance of serological tests of immunity, and durability and boosting of memory responses.

7. The study will be implemented by clinical trial units with experience in vaccine evaluation. VAANZ have proposed three units in Auckland, Rotorua and Christchurch to provide access to Managed Isolation and Quarantine staff and household contacts, Māori, Pasifika and healthcare workers.
8. HDEC review and approval will be obtained by the study investigators, utilising the rolling COVID-19 research review process. Medsafe submission is not required as no investigational products or new indications are involved. Māori consultation will be conducted with local Iwi near the study sites.
9. It is anticipated that funding for the study will be drawn from clinical research funds allocated to VAANZ, with a decision from the Ministry of Business Innovation and Employment anticipated following discussion with the Ministry of Health.
10. The study is anticipated to begin enrolling in April, subject to the required approvals and consultations in order to enrol Pfizer vaccine recipients.

Summary

11. VAANZ have proposed an observational study to assess safety, reactogenicity and immunogenicity of the four proposed COVID-19 vaccines for the New Zealand population. Funding is expected to come from clinical research funds previously allocated to VAANZ.
12. We recommend that the Ministry endorse the proposed study by VAANZ through:
 - working with VAANZ to reach out to each of the vaccine developers to inform them of the study and seek advice and input;
 - providing a letter of support for the study to selected DHBs indicating that the proposed study sites (Auckland, Rotorua and Christchurch) can administer COVID-19 vaccines to facilitate enrolling some vaccinees into studies.

Recommendations

It is recommended that you:

1.	note	VAANZ is planning to conduct an observational study to support the implementation of COVID-19 vaccines for the New Zealand population with funding primarily from clinical research funds previously allocated to them.	Yes/No
2.	agree	To the Ministry of Health signalling support to the Ministry of Business Innovation and Employment's investment within research.	Yes/No
3.	agree	To the Ministry of Health supporting VAANZ to reach out to each of the vaccine developers to inform them of the study and seek advice and input	Yes/No
4.	agree	That a letter of support for the study can be provided by the Ministry of Health to selected DHBs (Auckland, Rotorua, Christchurch) indicating that the proposed study sites can administer COVID-19 vaccines.	Yes/No


Signature _____
 [Name]
 [Title]

Date:



Signature _____
 [Name]
 [Title]

Date:


9(2)(ba)(i), 9(2)(b)(ii)




9(2)(ba)(i), 9(2)(b)(ii)




9(2)(ba)(i), 9(2)(b)(ii)




9(2)(ba)(i), 9(2)(b)(ii)




9(2)(ba)(i), 9(2)(b)(ii)



9(2)(ba)(i), 9(2)(b)(ii)



9(2)(ba)(i), 9(2)(b)(ii)



RELEASED UNDER
OFFICIAL INFORMATION ACT

Lisa Seng

From: Jonathan Lane
Sent: Wednesday, 24 February 2021 10:59 AM
To: Fran Priddy
Subject: RE: Supporting papers for CV TAG needed. [IN-CONFIDENCE:RELEASE EXTERNAL]

Perfect – thanks very much, Fran!

Regards

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hikina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Fran Priddy [mailto:fpriddy@malaghan.org.nz]
Sent: Wednesday, 24 February 2021 10:57 a.m.
To: Jonathan Lane
Cc: Hannah Walker; Oliver Jarvis
Subject: Fw: Supporting papers for CV TAG needed.

Hi Jonathan - Here is the briefing paper that MOH COVID vaccine TAG reviewed prior to the meeting on Friday.
Thanks,
Fran

Frances Priddy MD MPH FACP

Clinical Director
Vaccine Alliance Aotearoa New Zealand (VAANZ)
Ohu Kaupare Huaketo

9(2)(a)

E: fpriddy@malaghan.org.nz
W: www.malaghan.org.nz
A: PO Box 7060,
Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Janelle Duncan 9(2)(a)
Sent: Thursday, February 18, 2021 12:31 PM
To: Chris Hedlund 9(2)(a)

Cc: Fran Priddy <fpriddy@malaghan.org.nz>; Tim Hanlon 9(2)(a)

Subject: RE: Supporting papers for CV TAG needed.

Hi Chris,

Please find attached paper for post—event.

Best wishes,

Janelle

From: Tim Hanlon 9(2)(a)

Sent: Thursday, 18 February 2021 11:34 am

To: Chris Hedlund 9(2)(a)

Cc: Fran Priddy <fpriddy@malaghan.org.nz>; Janelle Duncan 9(2)(a)

Subject: RE: Supporting papers for CV TAG needed.

Hi Chris,

Janelle will be in touch with papers for tomorrow and to check on arrangements.

Thank you.

Best wishes

Tim

Dr Tim Hanlon

Post Event Pillar Lead | COVID-19 Vaccine and Immunisation Programme
Manatū Hauora | Ministry of Health

9(2)(a) | www.health.govt.nz



From: Chris Hedlund 9(2)(a)

Sent: Thursday, 18 February 2021 10:23 am

To: Pippa Scott <pippa.scott@otago.ac.nz>; Tim Hanlon 9(2)(a); fpriddy@malaghan.org.nz;

Helen Petousis-Harris <h.petousis-harris@auckland.ac.nz>

Cc: Chriselle Braganza 9(2)(a)

Subject: Supporting papers for CV TAG needed.

Please see below proposed agenda for CV TAG tomorrow and let me know if there are supporting papers for the items you will be leading. Agenda and supporting papers should be sent out by 1pm today, so your prompt action would be highly appreciated.

1. Welcome and apologies
2. Introductions
3. Overview of Immunisation Roll Out
4. Science updates – Pippa Scott
5. Vaccines for children – Pippa Scott
6. Pillar 7 activities – Tim Hanlon
 - Adverse Event Committee
 - Research projects - Fran Priddy
7. Baseline survey of Adverse Events – Helen Petousis-Harris
8. Next steps/Decisions Pending

Thank you,

Chris Hedlund | Coordinator | [She/Her](#)
Science & Technical Advisory | Rōpū tohutohu i te pūtaiao me te hangarau
COVID-19 Health System Response | Ministry of Health - Manatū Hauora | New Zealand

Statement of confidentiality: This e-mail message and any accompanying attachments may contain information that is IN-CONFIDENCE and subject to legal privilege.

If you are not the intended recipient, do not read, use, disseminate, distribute or copy this message or attachments.

If you have received this message in error, please notify the sender immediately and delete this message.

This e-mail message has been scanned for Viruses and Content and cleared by the Ministry of Health's Content and Virus Filtering Gateway

Lisa Seng

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Wednesday, 21 July 2021 9:03 AM
To: Jonathan Lane; Neil Dalphin
Subject: fyi... FW: NZH - Bryan Betty: Why aren't we producing a Covid vaccine?
Attachments: Bryan Betty_ Why aren't we producing a Covid vaccine_ - NZ Herald_ - www.nzherald.co.nz.pdf

<https://www.nzherald.co.nz/nz/bryan-betty-why-arent-we-producing-a-covid-vaccine/FCLHB5DOBRITJMJDWFOWFCWQOLM/>

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director (Chief Executive)

9(2)(a)
E: director@malaghan.org.nz
O: <http://orcid.org/0000-0002-5721-0442>
A: PO Box 7060, Wellington 6242, New Zealand
W: www.malaghan.org.nz



Harnessing the power
of the immune system

Lisa Seng

From: Jonathan Lane
Sent: Thursday, 22 July 2021 3:08 PM
To: Neil Dalphin
Cc: Graham LeGros
Subject: RE: fyi... FW: NZH - Bryan Betty: Why aren't we producing a Covid vaccine? [IN-CONFIDENCE: RELEASE-EXTERNAL]

Thanks, Graham. Neil, here's a link to the Stuff update:

[Covid-19: Calls for New Zealand to produce our own coronavirus vaccines | Stuff.co.nz](https://www.stuff.co.nz/health/covid-19/122111111-calls-for-new-zealand-to-produce-our-own-coronavirus-vaccines)

Regards

Jonathan Lane (he/him)
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Wednesday, 21 July 2021 9:03 am
To: Jonathan Lane <Jonathan.Lane@mbie.govt.nz>; Neil Dalphin <Neil.Dalphin@mbie.govt.nz>
Subject: fyi... FW: NZH - Bryan Betty: Why aren't we producing a Covid vaccine?

<https://www.nzherald.co.nz/nz/bryan-betty-why-arent-we-producing-a-covid-vaccine/FCLHB5DOBRIJMJDFWOFQOLM/>

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director (Chief Executive)

9(2)(a)

E: director@malaghan.org.nz
O: <http://orcid.org/0000-0002-5721-0442>
A: PO Box 7060, Wellington 6242, New Zealand
W: www.malaghan.org.nz

 **MALAGHAN**
INSTITUTE
Harnessing the power
of the immune system

Lisa Seng

From: Jonathan Lane
Sent: Monday, 3 May 2021 10:12 AM
To: Graham LeGros; Hannah Walker
Subject: RE: Melt your heart: Link to Brooklyn School and Malaghan Institute teaching us about vaccines and Covid19 [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks, Graham. Good to see the emerging researchers (the ones who talked with Minister Verrall recently) in front of the camera.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance - Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Graham LeGros [mailto:glegros@malaghan.org.nz]
Sent: Friday, 30 April 2021 2:36 p.m.
To: Jonathan Lane; Hannah Walker
Subject: Melt your heart: Link to Brooklyn School and Malaghan Institute teaching us about vaccines and Covid19

<https://youtu.be/hnQ8L3XYpc8>

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director of Research

9(2)(a)

E: director@malaghan.org.nz
O: <http://orcid.org/0000-0002-5721-0442>
A: PO Box 7060, Wellington 6242, New Zealand
W: www.malaghan.org.nz



Harnessing the power
of the immune system

Lisa Seng

From: Gail Marshall <gmarshall@malaghan.org.nz>
Sent: Wednesday, 9 June 2021 1:48 PM
To: Jonathan Lane; Hilary Morrison; Simon Rae
Cc: Graham LeGros; Fran Priddy
Subject: Malaghan media release re clinical study
Attachments: EMBARGOED MEDIA RELEASE PĀNUI PĀPĀHO New study into Pfizer-BioNTech COVID-19 vaccine to provide unique NZ data - June 2021.pdf

Hi Jonathan, Simon and Hilary

Please find attached a media release we're planning to put out tomorrow (Thursday) lunchtime re VAANZ's Pfizer vaccine clinical study. Fran Priddy, VAANZ Clinical Director has also sent it to Ian Towns, Tim Hanlon and Peter Crabtree and I've run it by MOH comms who see no issues/conflicts.

Let me know if you have any questions/concerns.

Gail

Gail Marshall
Head of Communications

9(2)(a)
E: gmarshall@malaghan.org.nz
W: www.malaghan.org.nz
A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

New study into Pfizer-BioNTech COVID-19 vaccine to provide unique NZ data

MEDIA RELEASE | PĀNUI PĀPĀHO EMBARGOED UNTIL 12PM 10/06/2021

A clinical study getting underway in Rotorua and Christchurch will provide valuable information on how our unique population responds to the Pfizer-BioNTech COVID-19 vaccine.

The study – 'Ka Mātau, Ka Ora' (from knowledge comes wellbeing) – is being led by Vaccine Alliance Aotearoa New Zealand – Ōhū Kaūpare Huaketo (VAANZ) and is being undertaken to inform the national COVID-19 strategy and ultimately enhance vaccine effectiveness and confidence.

"While the Pfizer-BioNTech vaccine has demonstrated efficacy and safety in pivotal clinical trials and real-world studies, it has not yet been studied in New Zealand," says the Malaghan Institute's Dr Fran Priddy, VAANZ Clinical Director. "We want to understand how New Zealanders' immune systems respond to the vaccine, particularly in populations likely at higher risk from COVID-19, such as Māori, Pasifika and the elderly."

Dr Priddy says with vaccine safety already being closely monitored and evaluated in New Zealand and internationally, Ka Mātau, Ka Ora will focus on characterising immune responses.

"Studies done post-vaccination in other countries have shown lower antibody responses in some groups, such as the elderly and those with obesity.

"We don't know if this translates to reduced effectiveness, but it will be very hard to measure effectiveness unless we have a large outbreak. So measuring immune responses is the best proxy right now for us in New Zealand."

Dr Priddy says our 'COVID-naïve' population will also offer unique data to global research. "Vaccine immune responses may differ in populations with little prior viral exposure, as is currently the situation in New Zealand."

There are ways to increase immune responses to vaccines says Dr Priddy, so if the study identifies responses that may impact effectiveness, this could be addressed in the future by booster shots, different vaccination schedules, or different vaccine types.

Clinical Immunologist Dr Maia Brewerton, who is on the Malaghan Institute's Te Urungi Māori advisory board, says that Aotearoa is in an enviable position due to our elimination strategy and measuring specific immune markers offers a useful alternative approach to assess the vaccine response amongst our people.

"Māori and Pasifika have a greater burden of conditions like heart disease associated with more severe COVID-19 disease, however even after we account for these conditions, Māori and Pasifika are still at increased risk of developing severe disease. We know there is more to learn and this research is important to help identify and understand any differences in the immune response which can guide the optimal vaccine approach for our people," she says.

"During the influenza pandemics last century, Māori experienced higher death rates and I hope with knowledge from research like this we can prevent a repeat of this story for Māori as we journey into the uncertain future of this COVID-19 pandemic together – Ka Mātau, Ka Ora."

Background

Ka Mātau, Ka Ora

Ka Mātau, Ka Ora (from knowledge comes wellbeing) is a clinical study to evaluate the immunogenicity of COVID-19 vaccine regimens in adults in New Zealand. It is being sponsored by the Malaghan Institute of Medical Research (as part of VAANZ) in collaboration with Pacific Clinical Research Network (PCRN), the Ministry of Health and the Human Vaccines Project.

Recruitment for Ka Mātau, Ka Ora is being undertaken at two PCRN study sites –Lakeland Clinical Trials in Rotorua and Southern Clinical Trials in Christchurch. The study aims to enrol at least 300 adult participants with a focus on Māori, Pasifika, older adults ≥65 years old, and those with co-morbidities associated with increased risk of COVID-19. The study will assess immune responses for up to 12 months after the last vaccine dose.

Anyone interested in getting involved in the study can contact:

Lakeland Clinical Trials | 07 347 7870 | info@lakelandtrials.com | lakelandtrials.com
Southern Clinical Trials | 0800 358788 | enquiries@sctrials.co.nz | sctrials.co.nz

Vaccine Alliance Aotearoa New Zealand – Ohu Kaupare Huaketo (VAANZ)

VAANZ is a partnership between the Malaghan Institute of Medical Research, the University of Otago and Victoria University of Wellington. As part of the Government's COVID-19 vaccine strategy, VAANZ is running a national COVID-19 vaccine evaluation and development platform to support the development of potential domestic and international second generation COVID-19 vaccines, focusing on vaccines that provide longer immunity, are effective against emerging coronavirus strains and could be manufactured domestically in the future. VAANZ is also helping build New Zealand's capability in vaccine development and production to ensure New Zealand is prepared for future pandemics.

www.malaghan.org.nz/infectious-diseases/covid-19/

Pacific Clinical Research Network (PCRN)

PCRN is a research network of clinical trial facilities attached to or part of general practice. The founding partners of the network are the Southern Clinical Trials group and Lakeland Clinical Trials Group in New Zealand and Paratus in Australia. PCRN has driven the evolution of clinical trial facilities in New Zealand over 20 years and is now the largest clinical trial network in New Zealand.

Media enquiries

Gail Marshall (Head of Communications, Malaghan Institute of Medical Research)
gmarshall@malaghan.org.nz | +64 21 360 432

www.malaghan.org.nz

Lisa Seng

From: Hilary Morrison
Sent: Wednesday, 9 June 2021 3:43 PM
To: Gail Marshall; Jonathan Lane; Simon Rae
Cc: Graham LeGros; Fran Priddy
Subject: RE: Malaghan media release re clinical study [UNCLASSIFIED]

Hi Gail, no issues this side. Thanks for the head's up!

Ngā mihi

Hilary Morrison

SENIOR ENGAGEMENT AND COMMUNICATIONS ADVISOR (Labour, Science & Enterprise)

Engagement, Communications and Ministerial Services Branch
Corporate, Governance and Information Group
Hikina Whakatutuki | Ministry of Business, Innovation & Employment

9(2)(a)

Level 4, 15 Stout Street, Wellington, P.O Box 1473, Wellington 6140, New Zealand



**MINISTRY OF BUSINESS,
INNOVATION & EMPLOYMENT**
HIKINA WHAKATUTUKI



From: Gail Marshall <gmarshall@malaghan.org.nz>

Sent: Wednesday, 9 June 2021 1:48 PM

To: Jonathan Lane 9(2)(a); Hilary Morrison 9(2)(a); Simon Rae

9(2)(a)

Cc: Graham LeGros <glegros@malaghan.org.nz>; Fran Priddy <fpriddy@malaghan.org.nz>

Subject: Malaghan media release re clinical study

Hi Jonathan, Simon and Hilary

Please find attached a media release we're planning to put out tomorrow (Thursday) lunchtime re VAANZ's Pfizer vaccine clinical study. Fran Priddy, VAANZ Clinical Director has also sent it to Ian Towns, Tim Hanlon and Peter Crabtree and I've run it by MOH comms who see no issues/conflicts.

Let me know if you have any questions/concerns.

Gail

Gail Marshall

Head of Communications

M: 021 360 432

E: gmarshall@malaghan.org.nz

W: www.malaghan.org.nz

A: PO Box 7060, Wellington 6242, New Zealand

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

From: Gail Marshall <gmarshall@malaghan.org.nz>
Sent: Thursday, 10 June 2021 12:00 PM
To: Gail Marshall
Subject: Media release: New study into Pfizer-BioNTech COVID-19 vaccine to provide unique NZ data
Attachments: MEDIA RELEASE PĀNUI PĀPĀHO New study into Pfizer-BioNTech COVID-19 vaccine to provide unique NZ data - June 2021.pdf

New study into Pfizer-BioNTech COVID-19 vaccine to provide unique NZ data

A clinical study getting underway in Rotorua and Christchurch will provide valuable information on how our unique population responds to the Pfizer-BioNTech COVID-19 vaccine.

The study, 'Ka Mātau, Ka Ora' (from knowledge comes wellbeing), is being led by Vaccine Alliance Aotearoa New Zealand – Ohu Kaupare Huaketo (VAANZ) and is being undertaken to inform the national COVID-19 strategy and ultimately enhance vaccine effectiveness and confidence.

"While the Pfizer-BioNTech vaccine has demonstrated efficacy and safety in pivotal clinical trials and real-world studies, it has not yet been studied in New Zealand," says the Malaghan Institute's Dr Fran Priddy, VAANZ Clinical Director. "We want to understand how New Zealanders' immune systems respond to the vaccine, particularly in populations likely at higher risk from COVID-19, such as Māori, Pasifika and the elderly."

Dr Priddy says with vaccine safety already being closely monitored and evaluated in New Zealand and internationally, Ka Mātau, Ka Ora will focus on characterising immune responses.

"Studies done post-vaccination in other countries have shown lower antibody responses in some groups, such as the elderly and those with obesity.

"We don't know if this translates to reduced effectiveness, but it will be very hard to measure effectiveness unless we have a large outbreak. So measuring immune responses is the best proxy right now for us in New Zealand."

Dr Priddy says our 'COVID-naïve' population will also offer unique data to global research. "Vaccine immune responses may differ in populations with little prior viral exposure, as is currently the situation in New Zealand."

There are ways to increase immune responses to vaccines says Dr Priddy, so if the study identifies responses that may impact effectiveness, this could be addressed in the future by booster shots, different vaccination schedules, or different vaccine types.

Clinical Immunologist Dr Maia Brewerton, who is on the Malaghan Institute's Te Urungi Māori advisory board, says that Aotearoa is in an enviable position due to our elimination strategy and measuring specific immune markers offers a useful alternative approach to assess the vaccine response amongst our people.

"Māori and Pasifika have a greater burden of conditions like heart disease associated with more severe COVID-19 disease, however even after we account for these conditions, Māori and Pasifika are still at increased risk of developing severe disease. We know there is more to learn and this research is important to help identify and understand any differences in the immune response which can guide the optimal vaccine approach for our people," she says.

“During the influenza pandemics last century, Māori experienced higher death rates and I hope with knowledge from research like this we can prevent a repeat of this story for Māori as we journey into the uncertain future of this COVID-19 pandemic together – Ka Mātau, Ka Ora.”

Background

Ka Mātau, Ka Ora

Ka Mātau, Ka Ora (from knowledge comes wellbeing) is a clinical study to evaluate the immunogenicity of COVID-19 vaccine regimens in adults in New Zealand. It is being sponsored by the Malaghan Institute of Medical Research (as part of VAANZ) in collaboration with Pacific Clinical Research Network (PCRN), the Ministry of Health and the Human Vaccines Project.

Recruitment for Ka Mātau, Ka Ora is being undertaken at two PCRN study sites –Lakeland Clinical Trials in Rotorua and Southern Clinical Trials in Christchurch. The study aims to enrol at least 300 adult participants with a focus on Māori, Pasifika, older adults ≥ 65 years old, and those with co-morbidities associated with increased risk of COVID-19. The study will assess immune responses for up to 12 months after the last vaccine dose.

Anyone interested in getting involved in the study can contact:

Lakeland Clinical Trials | 07 347 7870 | info@lakelandtrials.com | lakelandtrials.com
Southern Clinical Trials | 0800 358788 | enquiries@sctrials.co.nz | sctrials.co.nz

Vaccine Alliance Aotearoa New Zealand – Ohu Kaupare Huaketo (VAANZ)

VAANZ is a partnership between the Malaghan Institute of Medical Research, the University of Otago and Victoria University of Wellington. As part of the Government’s COVID-19 vaccine strategy, VAANZ is running a national COVID-19 vaccine evaluation and development platform to support the development of potential domestic and international second generation COVID-19 vaccines, focusing on vaccines that provide longer immunity, are effective against emerging coronavirus strains and could be manufactured domestically in the future. VAANZ is also helping build New Zealand’s capability in vaccine development and production to ensure New Zealand is prepared for future pandemics.

www.malaghan.org.nz/infectious-diseases/covid-19/

Pacific Clinical Research Network (PCRN)

PCRN is a research network of clinical trial facilities attached to or part of general practice. The founding partners of the network are the Southern Clinical Trials group and Lakeland Clinical Trials Group in New Zealand and Paratus in Australia. PCRN has driven the evolution of clinical trial facilities in New Zealand over 20 years and is now the largest clinical trial network in New Zealand.

Media enquiries:

Gail Marshall

Head of Communications

M: 021 360 432

E: gmarshall@malaghan.org.nz

W: www.malaghan.org.nz

A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

Lisa Seng

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Friday, 30 April 2021 11:56 AM
To: Prue Williams
Cc: Danette Olsen; Hannah Walker; Jonathan Lane
Subject: Outline of Malaghan Institute Proposal for a NZ RNA Nonmedicine platform to accelerate NZ Covid19 vaccine development

Attachments: 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

Follow Up Flag: Follow up
Flag Status: Completed

Dear Prue,

Please find attached an outline of a plan to introduce RNA Nanomedicine technology using the VAANZ platform which is already in place

As we keep hearing from near and far at the moment the RNA vaccine technology looks as though it has tremendous potential to accelerate and improve our Covid19 vaccine programme against Covid19. It is also looking to lead to new opportunities around having better medicines which are cheaper and more flexible and patient focused.

Please find attached a brief 1 pager, that outlines where I have managed to get to in bringing together likely funding sources to both maintain and accelerate the VAANZ programme to deliver on its goals and bring together an exciting new platform technology.

Of course there is at least 30 pages of number crunching quotes for equipment outlay etc etc done by Kylie price that make the whole thing real

The major elements include.

- 1) The VAANZ programme has produced an exciting and useful candidate vaccine for either booster shots to current vaccines or better in its own right at producing high titre antibodies that can neutralise the variant virus strains, we need to be able to push beyond the 1 year of funding we received to complete the task. (as far as I understand it there is no provision for continuing in the budget)
- 2) Therefore I have brought together a number of major donors and strategic partners who are willing to fund the laboratory outlay and capital equipment expenditure to fully equip NZ for conducting RNA vaccine development and manufacturing for clinical use. (This is a good option as it de-risks it for the Govt in terms of process and calls for proposals. And it really just builds upon the expertise that has already been brought together by the Govt investment in the VAANZ programme). All going well the investment will lead to a investment in the Wellington region around the exciting new RNA technologies by local strategic partners and overseas contracts. We see the development of RNA Nanomedicine technology to be essential for NZ's future.
- 3) The UK Govt. vaccine task force has contacted me about what is NZ doing, Australia Govt both local and Federal have announced commitments of \$100million to an Australian effort. Their RNA nanomedicine scientists would be keen to work with our skills in PC3 testing and GMP manufacturing of RNA vaccines.

There are a number of things that I have still to get in place but I am sending this to you now so you are informed with what we are about and I am happy to respond to any questions you might have

Of course these are just ideas at this point and they involve VAANZ commitments and only potential donor commitments. So I do not want to presuppose anything, Nor have you think we are distracting ourselves from VAANZ goals and milestones.

but I think I need to let you know just what the opportunity we think there is for NZ. And we would be happy to keep it at high level and relatively confidential and receive any feedback you might have. And whether it could fit into future scenarios for planning

But we have the ambition and it builds well on VAANZ.

Best Regards


Graham

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director of Research

9(2)(a)
E: director@malaghan.org.nz
O: <http://orcid.org/0000-0002-5721-0442>
A: PO Box 7060, Wellington 6242, New Zealand
W: www.malaghan.org.nz



Attachment has been redacted under: 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)



Lisa Seng

From: Prue Williams
Sent: Tuesday, 4 May 2021 11:49 AM
To: Graham LeGros
Cc: Danette Olsen; Hannah Walker; Jonathan Lane
Subject: RE: Outline of Malaghan Institute Proposal for a NZ RNA Nonmedicine platform to accelerate NZ Covid19 vaccine development [UNCLASSIFIED]

Kia ora Graham

Thank you for your email and for keeping me in the loop on ideas for future opportunities. We appreciate the work that VAANZ is doing and it is good to see the science successes you are having. While the contract is only for a short period of time, we are flexible about what work is done in the platform. So I encourage you to continue to work with Jonathan and Hannah about how to best use the available resources.

Regards
Prue

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Friday, 30 April 2021 11:56 am
To: Prue Williams 9(2)(a)
Cc: Danette Olsen 9(2)(a); Hannah Walker 9(2)(a); Jonathan Lane 9(2)(a)
Subject: Outline of Malaghan Institute Proposal for a NZ RNA Nonmedicine platform to accelerate NZ Covid19 vaccine development

Dear Prue,

Please find attached an outline of a plan to introduce RNA Nanomedicine technology using the VAANZ platform which is already in place

As we keep hearing from near and far at the moment the RNA vaccine technology looks as though it has tremendous potential to accelerate and improve our Covid19 vaccine programme against Covid19. It is also looking to lead to new opportunities around having better medicines which are cheaper and more flexible and patient focused.

Please find attached a brief 1 pager, that outlines where I have managed to get to in bringing together likely funding sources to both maintain and accelerate the VAANZ programme to deliver on its goals and bring together an exciting new platform technology.

Of course there is at least 30 pages of number crunching quotes for equipment outlay etc etc done by Kylie price that make the whole thing real

The major elements include.

- 1) The VAANZ programme has produced an exciting and useful candidate vaccine for either booster shots to current vaccines or better in its own right at producing high titre antibodies that can neutralise the variant virus strains, we need to be able to push beyond the 1 year of funding we received to complete the task. (as far as I understand it there is no provision for continuing in the budget)
- 2) Therefore I have brought together a number of major donors and strategic partners who are willing to fund the laboratory outlay and capital equipment expenditure 9(2)(ba)(i), 9(2)(b) to fully equip NZ for conducting RNA vaccine development and manufacturing for clinical use. (This is a good option as it de-risks it for the Govt in terms of process and calls for proposals. And it really just builds upon the expertise that has already been brought together by the Govt investment in the VAANZ programme). All going well the investment will lead to a 9(2)(ba)(i), 9 investment in the Wellington region around the exciting new RNA technologies by local

strategic partners and overseas contracts. We see the development of RNA Nanomedicine technology to be essential for NZ's future.

- 3) The UK Govt. vaccine task force has contacted me about what is NZ doing, Australia Govt both local and Federal have announced commitments of \$100million to an Australian effort. Their RNA nanomedicine scientists would be keen to work with our skills in PC3 testing and GMP manufacturing of RNA vaccines.

There are a number of things that I have still to get in place but I am sending this to you now so you are informed with what we are about and I am happy to respond to any questions you might have

Of course these are just ideas at this point and they involve VAANZ commitments and only potential donor commitments. So I do not want to presuppose anything, Nor have you think we are distracting ourselves from VAANZ goals and milestones.

but I think I need to let you know just what the opportunity we think there is for NZ. And we would be happy to keep it at high level and relatively confidential and receive any feedback you might have. And whether it could fit into future scenarios for planning

But we have the ambition and it builds well on VAANZ.

Best Regards

Graham

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)

Director of Research

9(2)(a)

E: director@malaghan.org.nz

O: <http://orcid.org/0000-0002-5721-0442>

A: PO Box 7060, Wellington 6242, New Zealand

W: www.malaghan.org.nz



Harnessing the power
of the immune system

Lisa Seng

From: Jonathan Lane
Sent: Tuesday, 2 March 2021 3:39 PM
To: 'Fran Priddy'
Subject: RE: Call re vaccine observational study biobank [IN-CONFIDENCE:RELEASE EXTERNAL]

I'm around until 6 today or else could talk tomorrow if that's better for you.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Jonathan Lane
Sent: Tuesday, 2 March 2021 2:07 p.m.
To: Fran Priddy
Subject: RE: Call re vaccine observational study biobank [IN-CONFIDENCE:RELEASE EXTERNAL]

Is 3 ok? I'm on a call til then.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Fran Priddy [mailto:fpriddy@malaghan.org.nz]
Sent: Tuesday, 2 March 2021 2:02 p.m.
To: Jonathan Lane
Subject: Re: Call re vaccine observational study biobank [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi Jonathan - Yes I will try you around 2:30p - in a meeting. Briefly, we will store leftover blood sample as well as a small amount collected for storage, for future use. Informed consent is obtained specifically for this.

Thanks,

Fran

Frances Priddy MD MPH FACP

Clinical Director
Vaccine Alliance Aotearoa New Zealand (VAANZ)
Ohu Kaupare Huaketo

9(2)(a)

E: fpriddy@malaghan.org.nz

W: www.malaghan.org.nz

A: PO Box 7060,
Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Jonathan Lane <Jonathan.Lane@mbie.govt.nz>
Sent: Tuesday, March 2, 2021, 11:16 AM
To: Fran Priddy <fpriddy@malaghan.org.nz>
Subject: Call re vaccine observational study biobank [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Fran. Wondering if you could call me when you're free – I just wanted to get a bit more detail on the biobank component of the observational study, just for context.

I haven't heard from Health about their deliberations yet – I've asked Tim and Janelle for an indication of time.

Regards

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS

Science System Investment and Performance - Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hikina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Friday, 9 July 2021 1:40 PM
To: Jonathan Lane; James Ussher; Bethany Andrews
Cc: Neil Dalphin
Subject: Re: OIA21-166: Official Information request - Briefings on Vaccine Alliance Aotearoa New Zealand and BioCell [IN-CONFIDENCE: RELEASE-EXTERNAL]

Thank You Jonathan,

At a first glance we have no problem with the release of the proposed information. Eg. It does not breach any contract confidentiality etc etc.

Let us have 24 hours with a detailed review and confirm this over the weekend

Thanks

Graham

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director (Chief Executive)

9(2)(a)
E: director@malaghan.org.nz
O: <http://orcid.org/0000-0002-5721-0442>
A: PO Box 7060, Wellington 6242, New Zealand
W: www.malaghan.org.nz



Harnessing the power
of the immune system

From: Jonathan Lane 9(2)(a)
Date: Friday, 9 July 2021 at 1:02 PM
To: "glegros@malaghan.org.nz" <glegros@malaghan.org.nz>, James Ussher <james.ussher@otago.ac.nz>, Bethany Andrews 9(2)(a)
Cc: Neil Dalphin 9(2)(a)
Subject: FW: OIA21-166: Official Information request - Briefings on Vaccine Alliance Aotearoa New Zealand and BioCell [IN-CONFIDENCE: RELEASE-EXTERNAL]

Hi, Graham, James and Bethany. The Minister of Science and Innovation has received an Official Information Act (OIA) request that includes VAANZ in its scope – relevant parts are below:

" briefings relating to the Vaccine Alliance Aotearoa New Zealand [...] and their contributions to the COVID-19 Vaccine Strategy.

In August last year it was announced that VAANZ had been granted \$10 million for the establishment of a COVID-19 vaccine development and evaluation platform.

I request copies of all briefings received by Minister Woods relating to this project, and any other projects VAANZ has undertaken with government funding, dated since the beginning of this year.

[...]

Please see the attached document for the material in scope for the OIA request.

- Note that much of it is publicly available either through:
 - public announcements about the Vaccine Strategy investments (eg <https://www.mbie.govt.nz/science-and-technology/science-and-innovation/international-opportunities/covid-19-vaccine-strategy/>).
 - information provided to the Economic Development, Science and Innovation Select Committee as part of the 2021/22 Estimates Examination ([bf6f197eedcefaf2fbd0f15498fbcdc3aab152a](https://www.parliament.nz/bf6f197eedcefaf2fbd0f15498fbcdc3aab152a) (www.parliament.nz)) – I have attached a Word document excerpting the relevant sections.
- Some of the material may not be publicly available currently. We seek your views on whether you have any concerns on this material being released, and, if so, what those concerns are.

Please respond by Tuesday 13 July. Please include both me and Neil in the reply (note I'm on leave Monday-Weds next week).

Regards

Jonathan Lane (he/him)

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS

Science System Investment and Performance : Labour, Science and Enterprise

Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Briefings/other with reference to VAANZ, since 2021

2021-4324 Annex 1 – Estimates Examination 2021-22

Annex 1 – Draft Topic Notes for RSI Estimates Examination Hearing

<https://mako.wd.govt.nz/otcs/llisapi.dll?func=ll&objaction=overview&objid=113283369>

“MBIE committed an initial \$29.75M from the Strategic Science Investment Fund to support the Strategy, including:

- o \$10M to establish the Vaccine Alliance Aotearoa NZ research platform.
- o \$15M to the Coalition for Epidemic Preparedness Innovations to support promising global research into COVID-19 vaccines.
- o \$2.88M to upgrade BioCell’s facilities to produce commercially significant quantities of human vaccines.”

“Government-funded Vaccine Alliance Aotearoa NZ has strengthened NZ’s links with the Coalition for Epidemic Preparedness Innovation.”

RSI 6-monthly report July-Dec 2020

<https://mako.wd.govt.nz/otcs/llisapi.dll?func=ll&objaction=overview&objid=110207505>

“Establishment of the Vaccine Alliance Aotearoa New Zealand (VAANZ) to connect New Zealand’s expertise to global research efforts.”

2021-3169 – Stocktake on Implementing the New Zealand Health Research Strategy

<https://mako.wd.govt.nz/otcs/llisapi.dll?func=ll&objaction=overview&objid=112984905>

“20. New Zealand COVID-19 vaccine development and manufacture

(action 10)

As part of the COVID-19 vaccine strategy \$10 million was used to support research in New Zealand, and \$5 million has been used to support potential manufacturing capability in New Zealand.”

2021-2864 Visit to Malaghan Institute of Medical Research, 1 April

<https://mako.wd.govt.nz/otcs/llisapi.dll?func=ll&objaction=overview&objid=111380235>

“As part of the COVID-19 Vaccine Strategy, MIMR was chosen in 2020 to host the Strategic Science Investment Fund (SSIF) COVID-19 vaccine research programme platform ‘Vaccine Alliance Aotearoa New Zealand’ (VAANZ). This platform is in partnership with the University of Otago and Victoria University Wellington. The platform is for \$10M and is contracted until November 2021. “

“In the invitation sent to you on 18 February 2021 (Annex Two), MIMR signalled a desire to discuss the following: a. MIMR’s performance hosting the Vaccine Alliance Aotearoa New Zealand (VAANZ)

b. MIMR’s ENABLE CAR T-cell (chimeric antigen receptor T-cell) cancer therapy

- c. MIMR's hookworm therapy programme to mitigate aggressive immune responses
- d. The Health Research Council's (HRC's) Independent Research Organisation (IRO) capability funding.

Vaccine Alliance Aotearoa New Zealand

11. VAANZ is hosted by MIMR and includes research partners at the University of Otago and Victoria University of Wellington. Their mission is to rapidly progress New Zealand's capability and capacity to develop and manufacture a COVID-19 vaccine in line with New Zealand's Vaccine Strategy and build New Zealand's ability for future vaccine development, production, supply and linkages with international vaccine research. The Platform supports New Zealand vaccine research capability and capacity development. 12. The VAANZ platform is designed to be flexible, adapting to a constantly changing environment around New Zealand's COVID-19 vaccine needs. To date, it has set up a platform for screening vaccine candidates; developed mouse models, assays and protocols; and carried out pre-clinical assessment on five vaccine candidates. The Platform is working with the Ministry of Health to perform post-rollout safety and efficacy research on New Zealanders receiving COVID-19 vaccines and is evaluating its suite of vaccine candidates to ensure its work is relevant to new SARS-COV-2 variants. "

"Annex Four: Suggested talking points

- For the COVID-19 vaccine research, and VAANZ, you may wish to ask:
 - o What has the Vaccine Alliance Aotearoa New Zealand achieved to date?
 - o What capability are you building for New Zealand's future vaccine research?
 - o How are you adapting your work as the environment around New Zealand's COVID-19 vaccine changes?"

2021-2672 IRANZ meeting 17-03-2021

<https://mako.wd.govt.nz/otcs/lisapi.dll?func=ll&objaction=overview&objid=111014739>

"The Malaghan Institute has hosted the Vaccine Alliance Aotearoa New Zealand platform, which supports COVID-19 Vaccine SSIF research since 2020. It is contracted to November 2021, with total funding of \$10M."

" You may wish to say:

- o The IROs' provided vital research and assistance with New Zealand's COVID-19 response. This is demonstrated in Malaghan hosting the Vaccine Alliance Aotearoa New Zealand programme, or the ways other IROs have contributed to government efforts to understand and respond to this pandemic."

2021-2419 Event Briefing – Minister Verrall meeting with Professor Richard Furneaux, 19 February 2021 <https://mako.wd.govt.nz/otcs/lisapi.dll?func=ll&objaction=overview&objid=110197674>

“Recent projects include work done by Dr Gerd Mittelstädt, working as part of the Vaccine Alliance Aotearoa New Zealand (VAANZ) to find a rapid way to produce the spike protein found in the SARS-CoV-2 virus, in order to assess potential vaccine components and support immunological testing.”

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Research on domestic manufacturing of a Covid-19 vaccine

The Committee notes the increase to Research, Science and Innovation: Strategic Science Investment Fund MCA in the 2020/21 Supplementary Estimates to support domestic and international research on the potential for domestic manufacturing of a Covid-19 vaccine.

Question 238: Please provide an update on expenditure against the \$29.750 million appropriation increase for research on the potential for domestic manufacturing of a Covid-19 vaccine?

Cabinet approved a one off-increase of \$29.750 million to the Strategic Science Investment Fund - Programmes in May 2020 to support initial investments under the COVID-19 Vaccine Strategy.

The Ministry has committed this funding as follows:

- \$10 million to establish the Vaccine Alliance Aotearoa NZ research platform. The platform was established to support the development of potential domestic and international COVID-19 vaccines by evaluating the safety and efficacy of vaccine candidates.
- \$15 million to Coalition for Epidemic Preparedness Innovations to support global COVID-19 vaccine research efforts
- \$2.88 million to the Auckland-based BioCell Corporation to upgrade its facilities to be able to manufacture commercially significant quantities of COVID-19 vaccines.

\$1.87 million is yet to be committed.

Question 239: What progress has been made, and what further investment is anticipated in this work? How much has been set aside for any further work in this area?

The COVID-19 Vaccine Strategy SSIF investments have progressed as follows:

- Vaccine Alliance Aotearoa NZ has set up a platform for screening vaccine candidates; developed mouse models, assays and protocols; carried out pre-clinical assessment on five vaccine candidates; and investigated vaccine candidates that can respond to new variants.
- Vaccine Alliance Aotearoa NZ is also studying how New Zealanders' immune systems respond to the Pfizer-BioNTech vaccine, particularly in populations likely at higher risk from COVID-19, such as Māori, Pasifika and the elderly.
- The Ministry's contribution to Coalition for Epidemic Preparedness Innovations has furthered its investments in global vaccine development, which has supported the development of successful vaccines from companies such as AstraZeneca and Novavax. The Ministry represents New Zealand on Coalition for Epidemic Preparedness Innovations Investors Council.

-
- The upgrades to BioCell's facilities are currently underway. BioCell has begun installing some of the equipment and is awaiting final deliveries from international suppliers.

The Ministry is investigating further options to improve domestic pandemic research and manufacturing. No additional funding has been set aside at this time.

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Lisa Seng

From: Fran Priddy <fpriddy@malaghan.org.nz>
Sent: Friday, 19 February 2021 5:19 PM
To: Jonathan Lane
Cc: Hannah Walker
Subject: Re: Proposed cohort study [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi Jonathan -

This is not my impression of the meeting. Rather there was general support for the study, some suggestions, and Ian Town wrapped the discussion by summarizing that the study had support and endorsement. Did you get a different impression from Tim? There were several suggestions but none of these required a new iteration, and most of them are already planned to be addressed but were too detailed for a synopsis.

I followed up with Tim to see if there would be a written communication from MOH regarding the outcome.

Perhaps we can touch base Monday to clarify.

Kind regards,
Fran

Frances Priddy MD MPH FACP

Clinical Director
Vaccine Alliance Aotearoa New Zealand (VAANZ)
Ohu Kaupare Huaketo

9(2)(a)
E: fpriddy@malaghan.org.nz
W: www.malaghan.org.nz
A: PO Box 7060,
Wellington 6242, New Zealand



From: Jonathan Lane 9(2)(a)
Sent: Friday, February 19, 2021 3:37 PM
To: Fran Priddy <fpriddy@malaghan.org.nz>
Cc: Hannah Walker 9(2)(a)
Subject: Proposed cohort study [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Fran. Hope you're doing well. I hear the Moh Vaccine TAG were generally supportive of the proposed work but wanted to consider a further iteration. When do you think that iteration will be back with Ministry of Health? Just working on timelines for MBIE's decision (which will include advice from Health).

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Jonathan Lane
Sent: Friday, 7 May 2021 2:06 PM
To: 'Graham LeGros'
Cc: Hannah Walker
Subject: RE: Query around contracting out VAANZ staff to support diagnostic developments for COVID19 antibodies [9(2)(b)(i), 9(2)(b)(ii)] [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Graham. I've raised your query below with Danette.

- 9(2)(a) FTE funded through VAANZ is solely for vaccine research-related work (including the observational study on the Pfizer vaccine that MBIE recently approved).
- Malaghan could choose to charge out 9(2)(a) time to a non-vaccine-related entity, but:
 - you should ensure you can still deliver the VAANZ programme (including the observational study on the Pfizer vaccine)
 - you should use the buy-out funds for work related to the VAANZ programme.

Happy to discuss anything if it's not clear.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Jonathan Lane
Sent: Thursday, 6 May 2021 11:59 a.m.
To: Graham LeGros; Hannah Walker
Subject: RE: Query around contracting out VAANZ staff to support diagnostic developments for COVID19 antibodies [9(2)(b)(i), 9(2)(b)(ii)] [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks, Graham. Will discuss with Danette and get back to you.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Graham LeGros [mailto:glegros@malaghan.org.nz]

Sent: Thursday, 6 May 2021 11:53 a.m.

To: Jonathan Lane; Hannah Walker

Subject: Re: Query around contracting out VAANZ staff to support diagnostic developments for COVID19 antibodies
9(2)(ba)(i), 9(2)(b)(ii) [IN-CONFIDENCE:RELEASE EXTERNAL]

Rough estimate would be 10%. 0.1 FTE for the next 6 months.

We are finding 9(2)(a) is very efficient at getting stuff done.

G

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)

Director of Research

9(2)(a)

E: director@malaghan.org.nz

O: <http://orcid.org/0000-0002-5721-0442>

A: PO Box 7060, Wellington 6242, New Zealand

W: www.malaghan.org.nz



From: Jonathan Lane 9(2)(a)

Date: Thursday, 6 May 2021 at 11:34 AM

To: "glegros@malaghan.org.nz" <glegros@malaghan.org.nz>, Hannah Walker

9(2)(a)

Subject: RE: Query around contracting out VAANZ staff to support diagnostic developments for COVID19 antibodies 9(2)(ba)(i), 9(2)(b)(ii) [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks, Graham. What's your rough estimate how much FTE a role like this would take (I'm assuming the role is clinical lead, based on your email below)?

Regards

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS

Science System Investment and Performance · Labour, Science and Enterprise

Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6

PO Box 1473, Wellington 6145

New Zealand

From: Graham LeGros [mailto:glegros@malaghan.org.nz]

Sent: Thursday, 6 May 2021 11:20 a.m.

To: Jonathan Lane; Hannah Walker

Subject: Query around contracting out VAANZ staff to support diagnostic developments for COVID19 antibodies for
9(2)(ba)(i), 9(2)(b)(ii)

Dear Jonathan, Hannah,

9(2)(ba)(i), 9(2)(b)(ii)

We think this sounds a useful thing to support. There is not the capability around in NZ 9(2)(ba)(i), 9(2)(b)(ii)

The question to you is should we charge them for 9(2)(a) time. Or should we just make it part of the support VAANZ can provide

Also there is the issue that we are picking and choosing and whether we are free to do that under VAANZ or whether we should do it under Malaghan Institute flag.

They of course will have to pay for the nuts and bolts of the clinical study.

Perhaps we can have a phone call to discuss

G

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director of Research

9(2)(a)

E: director@malaghan.org.nz

O: <http://orcid.org/0000-0002-5721-0442>

A: PO Box 7060, Wellington 6242, New Zealand

W: www.malaghan.org.nz



Harnessing the power
of the immune system

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Hannah Walker
Sent: Friday, 30 April 2021 3:15 PM
To: Oliver Jarvis
Cc: Jonathan Lane
Subject: Re: Report questions

Hi Oliver - Monday will be fine.
Hannah

Sent from my iPhone

On 30/04/2021, at 3:08 PM, Oliver Jarvis 9(2)(a) wrote:

Hi Hannah,

Our master IMS user is out of office, and I don't think we can get our responses into the system to meet today's deadline. Are you happy with us submitting Monday?

Alternatively could get into email form and submit this evening/ this weekend.

Kind regards
Oliver

Oliver Jarvis
Business Development Officer / Program Manager (VAANZ)

9(2)(a)

W: www.malaghan.org.nz

A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand

PA: PO Box 7060, Wellington 6242, New Zealand

<image001.jpg>

Lisa Seng

From: Oliver Jarvis 9(2)(a)
Sent: Monday, 3 May 2021 4:11 PM
To: Hannah Walker
Cc: Jonathan Lane
Subject: Re: Report questions [UNCLASSIFIED]

Please consider that email confidential information.

Apologies for this being a bit sloppy on our end, it's very hectic here at the moment.

Kind regards
Oliver

Oliver Jarvis
Business Development Officer / Program Manager (VAANZ)

9(2)(a)

W: www.malaghan.org.nz

A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand

PA: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Oliver Jarvis <ojarvis@malaghan.org.nz>
Date: Monday, 3 May 2021 at 4:09 PM
To: Hannah Walker <Hannah.Walker@mbie.govt.nz>
Cc: Jonathan Lane <Jonathan.Lane@mbie.govt.nz>
Subject: Re: Report questions [UNCLASSIFIED]

Hi Hannah, apologies for they delay, it should be submitted now.

I've also got some more information around the new viruses/mutations arrive in my inbox after the report was submitted, so please consider the following as part of the report.

9(2)(ba)(i), 9(2)(b)(ii)

[Redacted content]

9(2)(ba)(i), 9(2)(b)(ii)

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

[Redacted]

Kind regards
Oliver

Oliver Jarvis
Business Development Officer / Program Manager (VAANZ)

9(2)(a)

[Redacted]

W: www.malaghan.org.nz
A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand
PA: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Hannah Walker 9(2)(a)
Date: Monday, 3 May 2021 at 12:37 PM
To: Oliver Jarvis 9(2)(a)
Cc: Jonathan Lane 9(2)(a)
Subject: RE: Report questions [UNCLASSIFIED]

Hi Oliver – at what time can we expect the report to be submitted today?
Hannah

From: Oliver Jarvis 9(2)(a)
Sent: Friday, 30 April 2021 3:08 PM
To: Hannah Walker 9(2)(a)
Cc: Jonathan Lane 9(2)(a)
Subject: Report questions

Hi Hannah,

Our master IMS user is out of office, and I don't think we can get our responses into the system to meet today's deadline. Are you happy with us submitting Monday?

Alternatively could get into email form and submit this evening/ this weekend.

Kind regards
Oliver

Oliver Jarvis
Business Development Officer / Program Manager (VAANZ)

9(2)(a)
[Redacted]
[Redacted]

W: www.malaghan.org.nz
A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand
PA: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Hannah Walker
Sent: Monday, 3 May 2021 4:21 PM
To: Oliver Jarvis
Cc: Jonathan Lane
Subject: RE: Report questions [UNCLASSIFIED]

Kia ora Oliver – I have re-opened the portal – can you please submit this information where it fits.
Thanks
Hannah

From: Oliver Jarvis 9(2)(a)
Sent: Monday, 3 May 2021 4:10 PM
To: Hannah Walker 9(2)(a)
Cc: Jonathan Lane 9(2)(a)
Subject: Re: Report questions [UNCLASSIFIED]

Hi Hannah, apologies for they delay, it should be submitted now.

I've also got some more information around the new viruses/mutations arrive in my inbox after the report was submitted, so please consider the following as part of the report.

9(2)(ba)(i), 9(2)(b)(ii)

[Redacted content]

9(2)(ba)(i), 9(2)(b)(ii)

Kind regards
Oliver

Oliver Jarvis

Business Development Officer / Program Manager (VAANZ)

9(2)(a)

W: www.malaghan.org.nz

A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand

PA: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Hannah Walker 9(2)(a)
Date: Monday, 3 May 2021 at 12:37 PM
To: Oliver Jarvis 9(2)(a)
Cc: Jonathan Lane 9(2)(a)
Subject: RE: Report questions [UNCLASSIFIED]

Hi Oliver — at what time can we expect the report to be submitted today?
Hannah

From: Oliver Jarvis 9(2)(a)
Sent: Friday, 30 April 2021 3:08 PM
To: Hannah Walker 9(2)(a)
Cc: Jonathan Lane 9(2)(a)
Subject: Report questions

Hi Hannah,

Our master IMS user is out of office, and I don't think we can get our responses into the system to meet today's deadline. Are you happy with us submitting Monday?

Alternatively could get into email form and submit this evening/ this weekend.

Kind regards
Oliver

Oliver Jarvis

Business Development Officer / Program Manager (VAANZ)

9(2)(a)

W: www.malaghan.org.nz

A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand

PA: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Jonathan Lane
Sent: Monday, 12 April 2021 9:50 AM
To: Oliver Jarvis
Subject: RE: Database [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Oliver. Prue and I are meeting with the decision-maker tomorrow in person so would prefer to wait until then.

Regards

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hikina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Oliver Jarvis [mailto:ojarvis@malaghan.org.nz]
Sent: Monday, 12 April 2021 9:28 a.m.
To: Jonathan Lane
Subject: Database

Hi Jonathan,

Some good news, we've just received the quote for the database for the new study, and it's approx. [redacted] rather than the [redacted] budgeted (yay). I am however being hassled by the clinical team to sign this asap. Is there any way I can do so today, on top of the up to [redacted] guaranteed, or would you prefer to wait till tomorrow when we have a decision on the trial?

Given that it's one day, don't sweat too much about it unless it's an instant yes on your end.

Kind regards
Oliver

Oliver Jarvis
Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Huaketo

9(2)(a)

W: www.malaghan.org.nz

A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand

PA: PO Box 7060, Wellington 6242, New Zealand

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Lisa Seng

From: Jonathan Lane
Sent: Tuesday, 9 March 2021 11:02 AM
To: Graham LeGros; James Ussher; Oliver Jarvis
Cc: Hannah Walker; Mary Gower; Fernanda da Silva Tatley; Neb Svrzikapa
Subject: RE: Establishment phase report [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Graham, James and Oliver. This is a belated note to say thanks for the Establishment Phase report and to advise that MBIE has accepted the report.

As discussed, I'll be providing some further advice shortly on the Interim Progress Report/Forward-looking Plan you have submitted.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Oliver Jarvis 9(2)(a)
Sent: Friday, 4 September 2020 4:45 p.m.
To: Jonathan Lane
Cc: Hannah Walker; Graham LeGros; James Ussher; Mary Gower; Fernanda da Silva Tatley; Neb Svrzikapa
Subject: Establishment phase report

Hi Jonathan,

Please find attached the report on the Establishment phase of the VAANZ platform.

Kind regards
Oliver

Oliver Jarvis
Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Huaketo

9(2)(a)

W: www.malaghan.org.nz
A: PO Box 7060, Wellington 6242, New Zealand

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Lisa Seng

From: Jonathan Lane
Sent: Thursday, 10 June 2021 6:10 PM
To: Graham LeGros; Frances Priddy MD MPH (fpriddy@malaghan.org.nz)
Cc: Hannah Walker; Bethany Andrews; Neil Dalphin
Subject: RE: FYI. Frank. FW: CEPI announces new Scientific Advisory Committee [UNCLASSIFIED]

Hi, Graham. Thanks for forwarding the email below – and Fran, congratulations on your appointment to CEPI's Scientific Advisory Committee – great news!

Regards

Jonathan Lane (he/him)
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance - Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hikina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Thursday, 10 June 2021 9:13 am
To: Jonathan Lane 9(2)(a); Hannah Walker 9(2)(a); Bethany Andrews <bandrews@malaghan.org.nz>
Subject: FYI. Frank. FW: CEPI announces new Scientific Advisory Committee [UNCLASSIFIED]

Please send me Neil's email so I can include him.

Also FYI. See below

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director of Research

9(2)(a)

E: director@malaghan.org.nz
O: <http://orcid.org/0000-0002-5721-0442>
A: PO Box 7060, Wellington 6242, New Zealand
W: www.malaghan.org.nz



Harnessing the power
of the immune system

From: Fran Priddy <fpriddy@malaghan.org.nz>
Date: Thursday, 10 June 2021 at 9:10 AM
To: 9(2)(a)
Cc: Simon Rae 9(2)(a), Michael Contaldo 9(2)(a), Gary

Evans 9(2)(a), Graham LeGros <glegros@malaghan.org.nz>

Subject: Re: CEPI announces new Scientific Advisory Committee [UNCLASSIFIED]

Dear Peter -

Thank you for your kind email. I am excited to contribute to CEPI's scientific agenda for future pandemic vaccines and help represent NZ/Oceania perspectives. Sounds great to touch base once the new SAC convenes. I look forward to catching up with you then.

Kind regards,

Fran

Frances Priddy MD MPH FACP

Clinical Director

Vaccine Alliance Aotearoa New Zealand (VAANZ)

Oahu Kaupare Huaketo

9(2)(a)

E: fpriddy@malaghan.org.nz

W: www.malaghan.org.nz

A: PO Box 7060,

Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: fpriddy@gmail.com <fpriddy@gmail.com>

Sent: Thursday, June 10, 2021 9:02 AM

To: Fran Priddy <fpriddy@malaghan.org.nz>

Subject: FW: CEPI announces new Scientific Advisory Committee [UNCLASSIFIED]

From: Peter Bartlett 9(2)(a)

Sent: Thursday, June 10, 2021 12:56 AM

To: fpriddy@gmail.com

Cc: Simon Rae 9(2)(a); Michael Contaldo 9(2)(a); Gary Evans

9(2)(a); Graham LeGros <glegros@malaghan.org.nz>

Subject: FW: CEPI announces new Scientific Advisory Committee [UNCLASSIFIED]

Dear Fran,

I think we've only been included in copy in a couple of emails previously but thought I would drop you a note to properly introduce myself and say its very nice to see you have been appointed to the CEPI Scientific Advisory Committee! I am sitting on the CEPI Investor Council for New Zealand, so if there is anything you'd like to chat about please do to reach out. Once you have had a first meeting of the new SAC it would be great to set up a call to get your sense of it.

Kind regards,

PETER BARTLETT | Counsellor – Science and Innovation, Europe | New Zealand Space Agency and Ministry of Business, Innovation and Employment | New Zealand Mission to the EU, Avenue des Nerviens 9-31, Brussels [9\(2\)\(a\)](#)



**MINISTRY OF BUSINESS,
INNOVATION & EMPLOYMENT**
HIKINA WHAKATUTUKI



**NEW ZEALAND
SPACE AGENCY**

From: Richard Hatchett [9\(2\)\(a\)](#)

Sent: Wednesday, 9 June 2021 2:38 p.m.

To: Board Members [9\(2\)\(a\)](#); IC - Members [9\(2\)\(a\)](#)

Cc: CEPI Board [9\(2\)\(a\)](#); Joseph Simmonds-Issler [9\(2\)\(a\)](#); Frederik Kristensen

[9\(2\)\(a\)](#); Melanie Saville [9\(2\)\(a\)](#); Rachel Grant [9\(2\)\(a\)](#)

Samia Saad [9\(2\)\(a\)](#)

Subject: CEPI announces new Scientific Advisory Committee

Dear All,

I am delighted to today announce the new and returning members of [CEPI's Scientific Advisory Committee \(SAC\)](#). The SAC is our expert group which provides world-class scientific input and recommendations to CEPI Management and the Board to help guide our work.

The refreshed SAC will comprise of thirty-four expert individuals from a broad range of key disciplines. It will provide expert guidance and challenge and support our work to bring speed, scale, and access, to epidemic and pandemic vaccine development. SAC members will provide critical guidance and challenge to the progression of our COVID-19 efforts, as well as the design and implementation of our ambitious [CEPI 2.0 strategy](#).

The full list of members for the 2021-2024 CEPI SAC is now available [on the CEPI website](#). It includes some new members, as well as existing members who have served on the committee since its launch and will run an additional two-year term. Members will officially start this month, June 2021, and will be scheduled to meet on a quarterly basis.

It is a privilege to welcome back Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute of the University of Witwatersrand (South Africa), who will return as Chair of the SAC for a one-year term. Since its launch in 2018, Helen has played a pivotal leading role helping to shape and progress the Committee to advance our initial aims and, more recently, our COVID-19 response.

Michael King, an independent vaccine manufacturing consultant and member of CEPI's Research, Development and Manufacturing Investment Committee, has been newly selected as Vice-Chair. Additional members may join in the coming months to further expand the diversity of knowledge and background required to inform our CEPI 2.0 strategic R&D goals.

CEPI received a total of 155 applications in response to its call for experts to join the SAC. An exhaustive review process was conducted over March and April to select the new members, with decisions based on candidates' experience and expertise (specifically around CEPI 2.0 and our expanding scientific mandate), and was supported by Helen Rees, and Cherry Kang (Vice-Chair of the Board) and approved by the Executive and Investment Committee. We were eager to create an expert group with diverse cultural and scientific experiences to help advance CEPI's goals in an effective and efficient manner and therefore also prioritised the need for broad geographical and gender representation.

As we pass the torch to the next SAC, I would like to thank the inaugural members of the outgoing SAC (established in 2018) for their scientific expertise and assistance in creating what the committee is today. In addition to foreseeing the threat of an unknown 'Disease X' which allowed us to expedite rapid development of COVID-19 vaccines, our SAC members were also involved at critical junctures during the development of our core portfolio, as well as in supporting the response to major outbreaks of Lassa fever and Ebola, helping to define CEPI's unique scientific role in accelerating new tools for outbreak response.

Finally, I would like to recognise the SAC Team within CEPI's Vaccine R&D team who have orchestrated a smooth and successful selection process.

For further information on our governance groups and expert committees, you can visit [our website](#).

If you have any questions, do not hesitate to reach out to our SAC Support Team at cepisac@cepi.net.

Best regards,

Richard

Sensitivity: CEPI Internal

Sensitivity: CEPI Internal

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Fran Priddy <fpriddy@malaghan.org.nz>
Sent: Wednesday, 17 February 2021 12:55 PM
To: Jonathan Lane; Oliver Jarvis
Subject: Re: Hi, Fran/Oliver - wondering if you could send me Contact number /email for Tim Hanlon at Ministry of Health [IN-CONFIDENCE:RELEASE EXTERNAL]

Yes - here it is below

Dr Tim Hanlon

Post Event Pillar Lead | COVID-19 Vaccine and Immunisation Programme
Manatū Hauora | Ministry of Health

9(2)(a) | www.health.govt.nz

Frances Priddy MD MPH FACP

Clinical Director
Vaccine Alliance Aotearoa New Zealand (VAANZ)
Ohu Kaupare Huaketo

9(2)(a)

E: fpriddy@malaghan.org.nz
W: www.malaghan.org.nz
A: PO Box 7060,
Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Jonathan Lane 9(2)(a)
Sent: Wednesday, February 17, 2021 12:42 PM
To: Fran Priddy <fpriddy@malaghan.org.nz>; Oliver Jarvis 9(2)(a)
Subject: Hi, Fran/Oliver - wondering if you could send me Contact number /email for Tim Hanlon at Ministry of Health [IN-CONFIDENCE:RELEASE EXTERNAL]

Regards

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hikina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Lisa Seng

From: Jonathan Lane
Sent: Tuesday, 9 February 2021 1:39 PM
To: Oliver Jarvis
Cc: Hannah Walker
Subject: RE: Meeting [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Oliver. Does Thursday afternoon work for you/Graham/James/Fran, 3.30 or after ?

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance - Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Oliver Jarvis 9(2)(a)
Sent: Tuesday, 9 February 2021 9:49 a.m.
To: Jonathan Lane
Cc: Hannah Walker
Subject: Meeting

Hey Jonathan,

Is there a time this week that would work for a catch up?

Kind regards
Oliver

Oliver Jarvis
Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare, Huaketo

9(2)(a)

W: www.malaghan.org.nz
A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

Lisa Seng

From: Jonathan Lane
Sent: Wednesday, 14 April 2021 5:14 PM
To: Graham Le Gros (glegros@malaghan.org.nz); James Ussher; Frances Priddy MD MPH (fpriddy@malaghan.org.nz)
Cc: Oliver Jarvis 9(2)(a) Hannah Walker
Subject: Strategic Science Investment Fund Vaccine Platform/ VAANZ- informal advice on use of clinical trials funds [IN-CONFIDENCE:RELEASE EXTERNAL]

Dear Graham, James and Fran

Just to confirm the advice I gave Graham over the phone today, this is informal advice that MBIE has approved the use of clinical trials funds to conduct an observational study of vaccines being rolled out in New Zealand in 2021, and to extend the contract by approximately ten months to allow for the observational study. We'll send a formal letter through as soon as possible, and negotiate a contract variation with you in due course.

Regards

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

Lisa Seng

From: Jonathan Lane
Sent: Friday, 16 April 2021 3:25 PM
To: Fran Priddy; James Ussher; Graham LeGros
Cc: Oliver Jarvis; Hannah Walker
Subject: RE: Strategic Science Investment Fund Vaccine Platform/ VAANZ- informal advice on use of clinical trials funds [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks, Fran. We look forward to hearing more as the study progresses.
All the best for the ethics process.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance - Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Fran Priddy [mailto:fpriddy@malaghan.org.nz]
Sent: Thursday, 15 April 2021 9:14 a.m.
To: James Ussher; Jonathan Lane; Graham LeGros
Cc: Oliver Jarvis; Hannah Walker
Subject: Re: Strategic Science Investment Fund Vaccine Platform/ VAANZ- informal advice on use of clinical trials funds [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi Jonathan - Great news! Thanks very much for your support during this process. We will be submitting the study for ethics review now ASAP. Hope to give you an update and potential start date soon.
Kind regards,
Fran

Frances Priddy MD MPH FACP
Clinical Director
Vaccine Alliance Aotearoa New Zealand (VAANZ)
Ohu Kaupare Huaketo

9(2)(a)
E: fpriddy@malaghan.org.nz
W: www.malaghan.org.nz
A: PO Box 7060,
Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: James Ussher <james.ussher@otago.ac.nz>

Sent: Wednesday, April 14, 2021 5:24 PM

To: Jonathan Lane 9(2)(a); Graham LeGros <glegros@malaghan.org.nz>; Fran Priddy <fpriddy@malaghan.org.nz>

Cc: Oliver Jarvis 9(2)(a); Hannah Walker 9(2)(a)

Subject: Re: Strategic Science Investment Fund Vaccine Platform/ VAANZ– informal advice on use of clinical trials funds [IN-CONFIDENCE:RELEASE EXTERNAL]

Fabulous, thanks Jonathan.

Regards,

James

From: Jonathan Lane 9(2)(a)

Sent: Wednesday, 14 April 2021 5:14 PM

To: Graham Le Gros (glegros@malaghan.org.nz) <glegros@malaghan.org.nz>; James Ussher <james.ussher@otago.ac.nz>; Frances Priddy MD MPH (fpriddy@malaghan.org.nz) <fpriddy@malaghan.org.nz>

Cc: Oliver Jarvis 9(2)(a); 9(2)(a); Hannah Walker 9(2)(a)

Subject: Strategic Science Investment Fund Vaccine Platform/ VAANZ– informal advice on use of clinical trials funds [IN-CONFIDENCE:RELEASE EXTERNAL]

Dear Graham, James, and Fran

Just to confirm the advice I gave Graham over the phone today, this is informal advice that MBIE has approved the use of clinical trials funds to conduct an observational study of vaccines being rolled out in New Zealand in 2021, and to extend the contract by approximately ten months to allow for the observational study. We'll send a formal letter through as soon as possible, and negotiate a contract variation with you in due course.

Regards

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS

Science System Investment and Performance · Labour, Science and Enterprise

Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6

PO Box 1473, Wellington 6145

New Zealand

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

Lisa Seng

From: Jonathan Lane
Sent: Wednesday, 9 June 2021 10:22 AM
To: Bethany Andrews
Subject: RE: Today's VAANZ contract meeting- turn to Zoom meeting?

Thanks, Bethany. Teams works well for us.
I would also like to bring my colleague Neil Dalphin into the call - he is likely to be helping me out in the VAANZ contract so good to introduce him to you and Graham.

Regards

Jonathan Lane (he/him)
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS Science System Investment and Performance · Labour, Science and Enterprise Ministry of Business, Innovation & Employment / Hikina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

-----Original Message-----

From: Bethany Andrews <bandrews@malaghan.org.nz>
Sent: Wednesday, 9 June 2021 10:00 am
To: Jonathan Lane 9(2)(a)
Subject: Re: Today's VAANZ contract meeting- turn to Zoom meeting?

Hi Jonathan, that's not a problem to move the meeting today to online. I can will append a link to a Teams video call to the invite, or please feel free to send through a zoom link if you prefer. I'm afraid I don't have access to set-up zoom meetings here.

Thanks,
Bethany

On 9/06/21, 9:18 AM, "Jonathan Lane" 9(2)(a) wrote:

Hi, Bethany - unfortunately I am still recovering from a cold and am working from home today - wondering if we could do the meeting via Zoom rather than in person so I don't infect anybody...

Regards
Jonathan Lane
9(2)(a)

Sent from my iPhone

<https://aus01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.govt.nz%2F&data=04%7C01%7Cbandrews%40malaghan.org.nz%7C183011272f4e42eb21c508d92ac2ed7f%7Cc4b7458187b940849a77d4274ee489d4%7C0%7C0%7C637587838966075644%7CUnknown%7CTWFpbGZsb3d8eyJWljoiM C4wLjAwMDAiLCJQIjoiV2luMzliLCJBTiI6Ik1haWwiLCJXVCi6Mn0%3D%7C1000&reserved=0>
<<https://aus01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.govt.nz%2F&data=04%7C01%7Cbandrews%40malaghan.org.nz%7C183011272f4e42eb21c508d92ac2ed7f%7Cc4b7458187b940849a77d4274ee489d4%7C0%7C0%7C637587838966075644%7CUnknown%7CTWFpbGZsb3d8eyJWljoiM C4wLjAwMDAiLCJQIjoiV2luMzliLCJBTiI6Ik1haWwiLCJXVCi6Mn0%3D%7C1000&reserved=0>>

C01%7Cbandrews%40malaghan.org.nz%7C183011272f4e42eb21c508d92ac2ed7f%7Cc4b7458187b940849a77d4274ee489d4%7C0%7C0%7C637587838966075644%7CUnknown%7CTWFpbGZsb3d8eyJWlloiMC4wLjAwMDAiLCJQljoiv2luMzliLCJBTil6lk1haWwiLCJXVCI6Mn0%3D%7C1000&sdata=wQBVTW oQoaUYjvxmDvqKfu9DqddINyR2%2FyERtbY%2BhKk%3D&reserved=0> - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

RELEASED UNDER THE OFFICIAL INFORMATION ACT

Lisa Seng

From: Jonathan Lane
Sent: Wednesday, 3 March 2021 9:47 AM
To: Oliver Jarvis
Cc: Hannah Walker
Subject: RE: Trial approval [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Oliver. Yes, it's fine to incur costs to explore the option of doing the observational trial work.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Oliver Jarvis 9(2)(a)
Sent: Wednesday, 3 March 2021 8:21 a.m.
To: Jonathan Lane
Cc: Hannah Walker
Subject: Re: Trial approval [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks Jonathan.

9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

Oliver Jarvis
Program Manager: Vaccine Alliance Aotearoa New Zealand

9(2)(a)

W: www.malaghan.org.nz
A: PO Box 7060, Wellington 6242, New Zealand

From: Jonathan Lane 9(2)(a)
Sent: Monday, March 1, 2021 11:50:49 AM
To: Oliver Jarvis 9(2)(a)
Cc: Hannah Walker 9(2)(a)
Subject: RE: Trial approval [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Oliver. I understand from Fran that MoH are providing an indication of support this week. I am working on the MBIE approval subject to MoH's recommendation.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)
15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Oliver Jarvis 9(2)(a)
Sent: Monday, 1 March 2021 11:39 a.m.
To: Jonathan Lane
Subject: Trial approval

Hi Jonathan,

Do we have any update on approval for the trial? We need to start incurring costs this week with things like regulatory submission if we are going to get this moving in time.

Kind regards
Oliver

Oliver Jarvis
Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Hāketia

9(2)(a)
W: www.malaghan.org.nz
A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Lisa Seng

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Saturday, 17 April 2021 2:42 PM
To: Jonathan Lane; Hannah Walker; James Ussher
Cc: Oliver Jarvis
Subject: Update from 9(2)(a) who we have working at NIAID supporting our Covid19 programme. The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice
Attachments: 9(2)(ba)(i), 9(2)(b)(ii)

Dear Jonathan and Hannah,

I should have mentioned yesterday the fantastic job 9(2)(a) is doing in forging ahead and developing a wealth of experience working with the Covid 19 virus in preclinical models at the NIAID. See her latest results showing that the variants can infect wild type mice.

At this stage keep the information confidential. But could be recorded in your report the critical capability we are developing as part of the VAANZ programme with 9(2)(a) role over there.

We expect to have 9(2)(a) return beginning of next year and to have her in support of our programme here.

Graham

From: 9(2)(a)
Date: Saturday, 17 April 2021 at 2:05 PM
To: "glegros@malaghan.org.nz" <glegros@malaghan.org.nz>
Subject: Re: Any updates yet, thanks G Re: Dear 9(2)(a) any comment FW: The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice

Hi Graham,

Please find a brief summary of our preliminary results attached. 9(2)(ba)(i), 9(2)(b)(ii)

[REDACTED]

[REDACTED]

[REDACTED]

9(2)(a)

Attachment redacted under: 9(2)(ba)(i), 9(2)(b)(ii)

[REDACTED]

Lisa Seng

From: Jonathan Lane
Sent: Monday, 19 April 2021 2:39 PM
To: Graham LeGros; Hannah Walker; James Ussher
Cc: Oliver Jarvis
Subject: RE: Update from 9(2)(a) who we have working at NIAID supporting our Covid19 programme. The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks, Graham. Good to see you've got reach into the NIH. Worrying to see the variants can get into wild-type mice – I see there was some work done by the Institut Pasteur with similar findings:
<https://www.webmd.com/lung/news/20210325/covid-variants-detected-in-animals-may-find-host-in-mice>.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Graham LeGros [mailto:glegros@malaghan.org.nz]
Sent: Saturday, 17 April 2021 2:42 p.m.
To: Jonathan Lane; Hannah Walker; James Ussher
Cc: Oliver Jarvis
Subject: Update from 9(2)(a) who we have working at NIAID supporting our Covid19 programme. The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice

Dear Jonathan and Hannah,

I should have mentioned yesterday the fantastic job 9(2)(a) is doing in forging ahead and developing a wealth of experience working with the Covid 19 virus in preclinical models at the NIAID. See her latest results showing that the variants can infect wild type mice.

At this stage keep the information confidential. But could be recorded in your report the critical capability we are developing as part of the VAANZ programme with 9(2)(a) role over there.

We expect to have 9(2)(a) return beginning of next year and to have her in support of our programme here.

Graham

From: 9(2)(a)
Date: Saturday, 17 April 2021 at 2:05 PM
To: "glegros@malaghan.org.nz" <glegros@malaghan.org.nz>

Subject: Re: Any updates yet, thanks G Re: [REDACTED] any comment FW: The B1.351 and P.1 variants extend SARS-CoV-2 host range to mice

Hi Graham,

Please find a brief summary of our preliminary results attached. [REDACTED]

[REDACTED]

RELEASED UNDER THE OFFICIAL INFORMATION ACT

Lisa Seng

From: Hannah Walker
Sent: Wednesday, 28 April 2021 10:51 AM
To: glegros@malaghan.org.nz; James Ussher; fpriddy@malaghan.org.nz;
richard.blaikie@otago.ac.nz; 9(2)(a) [REDACTED]
Cc: Jonathan Lane; Hannah Walker; Danette Olsen; May Ryder
Subject: SSIF Vaccine Platform - Variation Letter [IN-CONFIDENCE:RELEASE EXTERNAL]
Attachments: Advice to SSIF Vaccine Platform VAANZ on changes in strategic direction and use of clinical trials funds.pdf

Tēnā koutou katoa

Please find attached a letter from Danette Olsen confirming the decision on use of some of the clinical trials funds and changes in source of strategic direction.

Please note that Jonathan is currently on leave until 3 May, if you have any questions please don't hesitate to contact me on 9(2)(a) [REDACTED].

I will be sending out details for the contract variation shortly.

Ngā mihi
Hannah

Hannah Walker

(She/her)

SENIOR INVESTMENT MANAGER

Strategic Investments

Science System Investment and Performance | Labour Science and Enterprise

Ministry of Business, Innovation & Employment | Te Manatū Pakihi, Auahatanga me Ngā Kaupapa ā-Mahi

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS

Science System Investment and Performance · Labour, Science and Enterprise

Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

Attachments to be redacted under: 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

RELEASED UNDER THE OFFICIAL INFORMATION ACT

Lisa Seng

From: Hannah Walker
Sent: Tuesday, 18 May 2021 4:14 PM
To: 9(2)(a)
Cc: Jonathan Lane; Hannah Walker
Subject: VAANZ SSIF Vaccine Platform: info [IN-CONFIDENCE:RELEASE EXTERNAL]
Attachments: 9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)
[Redacted attachments]

Follow Up Flag: Follow up
Flag Status: Completed

Kia ora Bethany

Really good to meet you today – as promised attached is information discussed with Oliver.

Reporting requirements and guidelines are attached (noting that with the variation these dates will change).

Also attached is the additional information we requested from Oliver (feedback letter) that was received 3 May – we are working through what information we still need and will be in touch. The Client Report attached is the information submitted by Oliver.

Finally – Jonathan and I will set-up a meeting to discuss the contract variation, attached are the emails that confirm the variation and refer to the information needed to kick this off in the system.

Don't hesitate to get in contact if you have any questions! Jonathan will be in touch about a meeting time soon.

Aku mihi
Hannah

Hannah Walker
(She/her)
SENIOR INVESTMENT MANAGER
Strategic Investments
Science System Investment and Performance | Labour Science and Enterprise
Ministry of Business, Innovation & Employment | Te Manatū Pakihi, Auahatanga me Ngā Kaupapa ā-Mahi

From: Jonathan Lane 9(2)(a)
Sent: Tuesday, 15 December 2020 2:07 PM
To: Oliver Jarvis 9(2)(a)
Cc: Hannah Walker 9(2)(a)
Subject: VAANZ SSIF Vaccine Platform: Final Guidelines/Spreadsheet [IN-CONFIDENCE:RELEASE EXTERNAL]

Kia ora, Oliver. Here are the final reporting guidelines and the project-level data reporting spreadsheet. You can now start the Initial Progress Report and Forward-Looking Plan in the MBIE portal. Heike can give you a login if you don't have one.

Regards

Strategic Science Investment Fund: Programmes –
COVID-19 Vaccine Platform

Progress Reporting Guidelines

1 August 2020 – 31 October 2021



RELEASED UNDER THE
OFFICIAL INFORMATION ACT

The material contained in this document is subject to Crown copyright protection unless otherwise indicated. The Crown copyright protected material may be reproduced free of charge in any format or media without requiring specific permission. This is subject to the material being reproduced accurately and not being used in a derogatory manner or in a misleading context. Where the material is being published or issued to others, the source and copyright status should be acknowledged. The permission to reproduce Crown copyright protected material does not extend to any material in this report that is identified as being the copyright of a third party. Authorisation to reproduce such material should be obtained from the copyright holders.

Published November 2020



Contents

INTRODUCTION	5
Key Actions and Dates for the Reporting Period	5
Key SSIF Documents to Support Reporting	5
Submitting Your Report	6
FORWARD-LOOKING PLAN	7
Content of your Forward-looking Plan	8
Section 1: Strategic Drivers	8
Section 2: SSIF Funding	8
Section 3: SSIF-funded Research and Activities	8
Section 4: Additional or Confidential Comment	9
PROGRESS REPORTS	10
Initial Progress Report	10
Final Progress Report	10
How to submit	10
How MBIE will use your Progress Reports	11
Content of your Progress Reports	11
Section 1: Funding Summary	11
Section 2: Public Statement	11
Section 3: Progress and Key Achievements	12
Section 5: Key Performance Indicators (KPIs)	13
Section 7: Project-Level Reporting	14
Section 9: Risks and Confidential Information	18

RELEASED UNDER THE OFFICIAL INFORMATION ACT

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Science Platforms

A combination of people, facilities, information and knowledge that provide a particular, ongoing science and innovation capability for New Zealand

Introduction

As an organisation that receives funding from the Strategic Science Investment Fund – Programmes (SSIF), you are responsible for reporting to MBIE on your progress and your forward-looking plan.

The SSIF Vaccine Platform receives funding for 15 months, from 1 August 2020 to 31 October 2021 (including an establishment phase). MBIE requires:

- > An Initial Progress Report and Forward-looking Plan by 20 January 2021
- > A Final Report by 30 November 2021.

These guidelines provide guidance on all reporting requirements.

Key Actions and Dates for the Reporting Period

	INITIAL PROGRESS REPORT AND FORWARD-LOOKING PLAN
Portal opens for submission	14 December 2020
Portal closes for submission	20 January 2021 (noon)
Discussion with MBIE	At next monthly catch-up
	FINAL PROGRESS REPORT
Portal opens for submission	1 November 2021
Portal closes for submission	30 November 2021 (noon)

Key SSIF Documents to Support Reporting

The key documents that shape SSIF reporting requirements are:

- > [SSIF Investment Plan 2017–2024: 2017 Update](#) – sets out the Government’s expectations of SSIF investment, and the Fund’s investment principles.
- > [SSIF Programmes Performance Framework](#) – summarises elements of reporting that will deliver transparent information on the progress towards outcomes of SSIF Programmes investments, and may be common across other MBIE investment mechanisms.
- > **Your Platform Plan** – describes, at a relatively high level, the strategic intent of your organisation’s SSIF investment, and how you plan to use SSIF funding over the term of your SSIF contract.

A Platform Plan outlines the strategic approach an organisation that receives SSIF funds will take to deliver the aim of the Government’s investment in strategic science. The Plan describes, for each SSIF Platform, how the research and associated people, facilities, knowledge and information will provide ongoing science and innovation capability for New Zealand. A Platform Plan, and any subsequent changes signalled in your Reports, provide a basis for discussions between an organisation and MBIE about how SSIF-funded research is addressing the SSIF investment signals.

- > **Your SSIF contract** – indicates the terms and conditions under which your organisation receives SSIF funding, including the reporting requirements.

Submitting Your Report

By the dates specified in the [Key Actions and Dates](#) table, we will open the IMS portal to accept your reports. The IMS portal will be set up to receive information. Whilst being drafted, your reports can be saved, printed and revised directly in the IMS portal. Once you are satisfied with your reports, please formally submit.

For all IMS portal queries, e-mail or call the Investment Operations Team:

Email imssupport@mbie.govt.nz

Phone 0800 693 778 (Monday to Friday, 8:30am to 4:30pm)

RELEASED UNDER THE
OFFICIAL INFORMATION ACT



Forward-looking Plan

The SSIF Vaccine Platform is intended to:

- > operate flexibly and adaptably in line with the vaccine strategy and strategic direction from the COVID19 Vaccine Task Force
- > be able to nimbly redirect research activity in line with changes in the global vaccine environment
- > take a "New Zealand Inc" approach to achieving the Platform's mission.

Your Platform Plan includes an initial plan to deliver SSIF Vaccine Platform outcomes. MBIE expects that aspects of the Platform Plan may need to change given the intention for flexibility and adaptation outlined above.

Your Forward-looking Plan (FLP) should outline how you will use SSIF funding over the remainder of the contract period (1 January to 31 October 2021) to deliver the SSIF outcomes outlined in your Platform Plan, including any changes as outlined above.

The FLP provides an opportunity to:

- > confirm that your SSIF investment, in accordance with the strategic intent outlined in your Platform Plan, is still appropriate, or
- > explain the need for any changes to your SSIF investment strategy, and
- > identify any risks to the delivery of the Platforms' objectives.

It needs to be clear to MBIE from your FLP how you will use SSIF for the remainder of the contract period. You can provide information as brief statements. However, these must include sufficient information to enable informed discussion of the topic.

We do not impose a word limit for your FLP but we expect 1500-2000 words to be sufficient to provide the information needed.

Focus on change

The FLP should focus on any changes, internal or external to your organisation, which might affect how you plan to use your SSIF funding, or the direction or delivery of your Platform over the coming year.

- > Changes in external drivers that might impact on your SSIF investment. (For example, what strategic direction has the Task Force provided? Has the external environment relating to the SSIF Vaccine investment changed? How will the Platform respond to these factors?)
- > Significant changes to funding allocation to projects, impacts or science priorities. (For example, why is a shift in the allocation of funds necessary? How has it changed and what impact did the shift have on your overall investment?)
- > Planned changes in research, impacts or other activities signalled in your Platform Plan that will have a material effect on the science your SSIF investment will deliver. (For example, why did you choose this approach? What, if any, strategic trade-offs have you needed to make?)
- > Explanation of any work in the year ahead that will be conducted as a result of delayed progress.
- > New risks to the delivery of the Platform objectives you have identified.
- > Specific initiatives, in particular regarding Vision Mātauranga, capability development and collaborations.

- > Other comments on your SSIF investment you wish MBIE to be aware of, and, if no significant changes have occurred, you should provide the rationale for that.

A section is included in IMS for you to provide any additional comments you wish to draw to MBIE's attention. You can also include confidential information in this section.

Content of your Forward-looking Plan

In IMS, complete the following sections.

1. Strategic drivers
2. SSIF funding
3. SSIF-funded research and activities
4. Additional or confidential comments

Section 1: Strategic Drivers

For your SSIF investment briefly outline the internal or external drivers that have most influenced your SSIF plans for the remainder of the contract. Comment on any changes in key drivers of your SSIF investment, and explain how you will respond to these.

Section 2: SSIF Funding

For your total SSIF investment indicate the magnitude of, and explain reasons for, any significant shifts in funding of impacts, key science areas, alignment of funds.

If no change to the funding allocation described in your Platform Plan is planned, simply state 'as per Plan'.

Section 3: SSIF-funded Research and Activities

Describe your focus for the remainder of the contract period and what you expect to achieve within the Platform, under each of the following sub-headings:

- > Strategic intent
- > Impact
- > Science excellence
- > Horizons
- > Investing in people
- > Vision Mātauranga
- > Domestic and international collaboration

Explain the rationale for the approach you have chosen. If your planned research or activities differ from the direction described in your Platform Plan, explain why the change is necessary, and what, if any, strategic trade-offs you have needed to make.

If no change to the approach outlined in your Platform Plan is planned, what assures you this approach is still appropriate?

Section 4: Additional or Confidential Comment

Use this section to comment on any other aspect of your SSIF investment that you would like to draw to MBIE's attention.

As per your SSIF Investment Contract, MBIE will treat in confidence any information in this section or elsewhere in the document. However, release of any information held by MBIE may be required under the [Official Information Act](#). Please clearly mark as 'Confidential' any information that you consider to be particularly sensitive or commercial in confidence.

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Progress Reports

Progress reporting is the mechanism MBIE uses to demonstrate accountability in its investment of SSIF funds, and to understand how you have invested SSIF funding. Progress Reports also help MBIE to understand and demonstrate the performance of the science system.

MBIE requires an Initial Progress Report and a Final Progress Report for the SSIF Vaccine Platform. These reports will:

- > give MBIE visibility over the investment to enable effective performance management
- > allow MBIE and partner agencies to report back to government regularly.

The reporting requirements set out in this section cover both Progress Reports. However, the Progress Reports will cover different time periods.

Initial Progress Report

This report covers the period from the beginning of the Full Contract of the SSIF Vaccine Platform (1 August 2020) to 31 December 2020. The report is due with MBIE at noon on 20 January 2021.

Final Progress Report

This report covers the period from the beginning of the Full Contract of the SSIF Vaccine Platform (1 August 2020) to the end of the contract (31 October 2021). It should provide sufficient information to allow MBIE to understand progress over the entire contract period. Your Progress Report should describe your SSIF-funded science and related activities, using brief narrative and highlights or significant achievements to illustrate how your SSIF-funded science aligns with, or addresses, the SSIF investment signals.

Your Progress Report provides you the opportunity to:

- > demonstrate progress against the strategic intent of your Platform Plan
- > highlight what you have achieved using SSIF funding during the reporting period against the SSIF investment signals.

Formal Progress Reports will be supplemented by scheduled monthly meetings between Platform leads and MBIE to discuss the progress of the Platform Plan.

How to submit

Your Progress Reports are submitted via MBIE's IMS portal. All information is entered directly (this can be cut and pasted from Word documents) into the portal, with the exception of Key Performance Indicators (KPIs) and project-level data, for which spreadsheets will be provided for you to complete and upload to IMS.

For the **Initial Progress Report**, the IMS portal will open to receive reports on **14 December 2020**, and will close at noon on **20 January 2021**.

For the **Final Progress Report**, the IMS portal will open to receive reports on **1 November 2021**, and will close at noon on **30 November 2021**.

How MBIE will use your Progress Reports

Your **Initial Progress Report**, together with the **Forward Looking Plan**, will allow MBIE to assess progress towards achievement of the objectives of your Platform to date and your plans for the remainder of the contract. MBIE will provide feedback on both documents. If MBIE considers there are substantive issues to address in either past performance or future plans, we will discuss these with you, either in writing or through a formal meeting.

Your **Final Progress Report** will allow MBIE to assess progress towards achievement of the objectives of your Platform over the life of the contract (including the Establishment Phase). We will provide written feedback to you on that report.

After each report, a summary of your progress, emphasising science achievements and their contribution to impacts, may be made available to the Minister of Research, Science and Innovation (for information).

Content of your Progress Reports

In IMS, complete the following sections.

1. Funding Summary
2. Public Statement
3. Progress and Key Achievements
4. Key Performance Indicators (KPIs)
5. Project-Level Information (*excel spreadsheet upload into JMS*)
6. Risks and Confidential Comments

Section 1: Funding Summary

For transparency and accountability, we need to know your total SSIF expenditure (excluding GST) for the reporting period.

If there is a significant variance between the total SSIF funding you have received for the reporting period and the amount you have spent, explain the reason(s) why. Explanation is mandatory if the variance between your SSIF income and expenditure for the period is more than \$100,000 (excluding GST).

The expenditure figure you provide in this section should equal the total expenditure on your [project-level Excel spreadsheet](#).

Section 2: Public Statement

The Public Statement helps provide transparency in the science that the SSIF is purchasing.

Your Public Statement should demonstrate progress against your strategic goals, and we may publish this on the MBIE website. We will ask for it to be re-worked if the summary does not fit the requirements.

Provide a summary of **SSIF highlights and achievements**, consisting of:

- > Selected highlights and key achievements in science and capability. Please ensure it reads as a cohesive and compelling summary.
- > Web links for additional information, for example, links to case studies.
- > Name, logo (optional), and web address of the Platform host.
- > Name (optional), phone number and/or email address of a contact who can provide more information.

You should ensure that the text you provide can be freely used by any interested party without breaching commercial sensitivity or confidentiality agreements.

The Public Statement should be no longer than 300 words.

Section 3: Progress and Key Achievements

Comment on progress and key achievements during the reporting year by providing a narrative against each of the SSIF investment signals below.

- > Strategic intent
- > Impact
- > Science excellence
- > Horizons
- > Investing in people
- > Vision Mātauranga
- > Domestic and international collaboration

We do not impose a word limit, but we expect 1500-2000 words should be sufficient to complete this section.

When writing your report, we **recommend** that you:

- > clearly explain the rationale, results and value of your SSIF investment
- > consistently consider the "so what" question (clearly explaining significance and relevance of your research)
- > comment on any significant change from your contracted Platform Plan in the science or activities you have undertaken during the reporting period
- > comment on any risks you have identified to the delivery of the Platforms objectives, and mitigating actions
- > provide evidence you have responded to strategic direction from the COVID19 Vaccine Task Force, and to MBIE feedback during the reporting period.

We strongly encourage focussed and concise narratives. The focus of your narrative should be on how science and capability have significantly contributed to the strategic intent, expected impacts and other deliverables as outlined in your Platform Plan.

Ensure a consistent use of outcomes-focussed language, rather than process-focussed, to illustrate achievements against each of the investment signals, eg:

- > **Science excellence:** Our SSIF-funded analysis of X showed Y. Results were presented in an invited keynote address to the 25th International Congress of Modellers, and published in the Global Journal of Excellent Science.
(rather than "SSIF-funded research on X was the subject of an invited keynote address at an international conference, held in America in March 2017.")
- > **International collaboration:** Collaboration with the University of Ireland expanded our ability to forecast X, by combining the University's expertise in Y with our knowledge of Z.
(rather than "we initiated a new collaboration with researchers from the University of Ireland.")

Section 5: Key Performance Indicators (KPIs)

All SSIF recipients report against contracted KPIs based on the investment signals in the SSIF Investment Plan.

MBIE is interested to know:

- > the status of each of your KPIs (e.g. achieved, on track, not achieved)
- > reasons for any non-achievements, and your revised plans/approach to achievement.

You will be able to input directly into your KPIs into IMS. You will use drop-down lists and comment boxes in the spreadsheet to indicate and comment on the status of each of your KPIs.

Where the status is "on track" or "achieved", provide metrics or brief explanation that supports your selection of status. For KPIs that are not on track or have not been achieved by the due date, comment on reasons for non-achievement, and explain the actions you will take to ensure completion, and indicate the revised timeframe to completion.

RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Section 7: Project-Level Reporting

Although the focus of SSIF is on investment at a strategic level, MBIE also collects project-level information for each Platform. Project-level information on SSIF investment is required:

- > **as a record of your SSIF income and expenditure, the science the SSIF investment is purchasing, and the capability being supported by SSIF**
 MBIE's interest in SSIF at project level is primarily to provide a snapshot of SSIF investment that ensures investment transparency, and complements the high-level overview of how you intend to invest SSIF funding described in your Platform Plan.

- > **to provide data in a format that will support transition to NZRIS-compliant reporting**
 MBIE may need to seek additional project-level information outside of the reporting cycle to respond to advice requests from Ministers.

Excel spreadsheet

An Excel spreadsheet will be provided by email for project-level information for your total SSIF investment. The spreadsheet contains mandatory and optional data about each of your projects. The table below outlines which information reflects NZRIS compliant data requirements.

Mandatory data demonstrate transparency in your SSIF investment (finances and science).

Optional data about your projects reflect some of the requirements for NZRIS-compliant reporting.

Completing the project-level spreadsheet

You will enter a single project covering the entire SSIF Vaccine Platform investment in the reporting period.

The spreadsheet provides the opportunity (in the Non-Research Expenditure column) to differentiate between research expenditure and project expenditure in support of your SSIF investment, e.g. membership fees (at institute level), development and/or writing SSIF grants, capability building expenditure etc.

Content of the Excel spreadsheet

FIELD	DESCRIPTION
Mandatory data	
Tab 1.1 Project Title	Provide a descriptive (science-focused) title.
Tab 1.1 Local Project Identifier (NZRIS)	If available , indicate the internal code for your project. This code is unique for your organisation. If your organisation does not have an applicable code please type N/A.
Tab 1.1 Project Description (NZRIS)	Describe what was done; why it was needed; expected impact or outcomes, and how SSIF will enable or contribute to these. Your rationale for SSIF investment in this area and the contribution it will make should be obvious from the project description you provide.

FIELD	DESCRIPTION
Tab 1.1 SSIF Funding (Resource value)	<p>\$ (excluding GST) spent or committed to the project from 1 August 2020 to the end of the reporting period.</p> <p>For the Final Progress Report, your total expenditure across all projects should equal your annual SSIF budget. If not, explain the variance in Funding Summary text box in the narrative section of your report in IMS.</p>
Tab 1.1 Non-Research Expenditure	<p>\$ (excluding GST) spent or committed to the project from 1 August 2020 to the end of the reporting period that does not directly relate to research expenditure.</p>
Tab 1.1 Start date (NZRIS)	<p>Indicate the start date of the project.</p>
Tab 1.1 End date (NZRIS)	<p>Indicate the anticipated end date of the project.</p>
Tab 1.1 Project Status (NZRIS)	<p>State the status of the project.</p> <p>Select from the drop-down list provided. Options are: Active; On Hold; Completed; Partially Completed; Cancelled.</p>
Tab 1.1 Project Type (NZRIS)	<p>Select which NZRIS project type category best describes the project.</p> <p>Select from the drop-down list provided. Options are: Frascati R&D; Non-Frascati R&D Innovation; Scientific services and products; Knowledge transfer, outreach and extension; Commercialisation; Administration; Infrastructure.</p> <p>More detailed definitions of each category are available in Section 8.a Project Project Type Utilisation of the NZRIS Data Specification.</p>
Tab 1.1 Alignment with Vision Mātauranga	<p>Indicate which Vision Mātauranga category provided best describes the project.</p> <p>Select from the drop-down list provided. Options are: Kaupapa Māori research; Māori centred research; Research involving Māori; Research relevant to Māori; Research not specifically relevant to Māori/ not involving Māori; N/A (if non-research expenditure).</p>

FIELD	DESCRIPTION
<p>Tab 1.1 ANZSRC Type of Activity (NZRIS)</p>	<p>List the ANZSRC Type of Activity that best describes the project. Aggregated data against projects should be roughly consistent with your horizons balance.</p> <p>Select from the drop-down list. Options are: Pure basic research; Strategic basic research; Applied research; Experimental development; N/A (if non-research expenditure).</p> <p>ANZSRC codes are available online at Statistics New Zealand or the Australian Bureau of Statistics.</p>
<p>Tab 1.2 Project Personnel (NZRIS)</p>	<p>For your primary person, indicate the below. If you do not have this data please ensure you do still fill out a row for this project, but select N/A for each column.</p> <ul style="list-style-type: none"> > Person Identifier Type. Select from the drop down list provided. Options are: Local; ORCID ID; ISNI; SCOPUS; Researcher ID; Other Identifier. > Person Identifier Value <p>Also indicate:</p> <ul style="list-style-type: none"> > Role. Select from the drop down list provided. Options are: Lead Contributor, Other Named Contributors, Other Contributors; Supporting Staff; Technician; Collaborator. > Start Date > Estimated FTE allocation (to one decimal place, eg 0.3) on the project
<p>Tab 1.3 Research subcontracting</p>	<p>List all subcontracts from this project to another organisation to contribute critical research capability. Do not include subcontracts related to service providers unless the service they provide is an essential part of the research project.</p> <p>Include funding figures (excl. GST)</p> <p>Under the Domestic and International Collaboration section in your narrative Progress Report, please provide a (high-level) overview of the expertise your subcontractors bring to your SSIF research.</p>
<p>Tab 1.5 ANZSRC SEO coding (NZRIS)</p>	<p>Please enter up to three of the relevant 6-digit SEO codes that best describe the intended outcomes of the project in the "ANZSRC Code" column.</p> <p>The Division/Group/Field or Objective columns will be auto-populated from your choice of ANZSRC Code.</p> <p>Estimate the proportion of the project relevant to each of the codes. Your estimates should total 100%.</p>



FIELD	DESCRIPTION
Tab 1.5 ANZSRC Field of Research (FOR) codes (NZRIS)	<p>Please enter up to three of the relevant 6-digit FOR codes that best describe the <u>main research discipline(s)</u> contributing to the project in the "ANZSRC Code" column.</p> <p>The Division/Group/Field or Objective columns will be auto-populated from your choice of ANZSRC Code.</p> <p>Estimate the proportion of the project relevant to each of the codes. Your estimates should total 100%.</p> <p>ANZSRC codes are available online at Statistics New Zealand or the Australian Bureau of Statistics.</p>
Optional data	
Tab 1.1 Keywords (NZRIS)	<p>List your choice of keywords that describe topics and/or themes of significance to the project.</p> <p>Keywords may enable you to provide a more precise description than is possible using ANZSRC codes.</p> <p>Please separate keywords with commas.</p>
Tab 1.2 Other project personnel (NZRIS)	<p>If you wish you may enter other personnel working on the project. These data are optional.</p> <p>Due to the functionality of the spreadsheet, other personnel should be entered on tab 1.2 Project personnel in green-shaded cells</p> <p>Name the (other) personnel working on the project. For each person named, indicate if possible:</p> <p>Person Identifier Type. Select from the drop down list provided. Options are: Local; ORCID ID; ISNI; SCOPUS, Researcher ID; Other Identifier.</p> <ul style="list-style-type: none"> > Person Identifier Value <p>Also indicate:</p> <ul style="list-style-type: none"> > Role. Select from the drop down list provided. Options are: Lead Contributor, Other Named Contributors, Other Contributors; Supporting Staff; Technician; Collaborator. > Start Date > Estimated FTE allocation (to one decimal place, e.g. 0.3) on the project

Section 9: Risks and Confidential Information

Risks

Briefly discuss any barriers or risks that may constrain your progress towards the Platform objectives.


Confidential Information

Use this section to comment on any information that you consider as particularly sensitive or as commercial that you wish to draw to MBIE's attention.

As per your SSIF Investment Contract, MBIE will treat in confidence any information in this section or elsewhere in the document. However, release of any information held by MBIE may be required under the [Official Information Act](#).

RELEASED UNDER THE
OFFICIAL INFORMATION ACT





**MINISTRY OF BUSINESS,
INNOVATION & EMPLOYMENT**
HĪKINA WHAKATUTUKI

newzealand.govt.nz

Lisa Seng

From: Jonathan Lane
Sent: Thursday, 20 May 2021 4:37 PM
To: Bethany Andrews; Hannah Walker
Subject: RE: VAANZ SSIF Vaccine Platform: info [IN-CONFIDENCE:RELEASE EXTERNAL]

Thanks very much, Bethany.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance - Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)
15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Bethany Andrews 9(2)(a)
Sent: Wednesday, 19 May 2021 4:05 p.m.
To: Hannah Walker
Cc: Jonathan Lane
Subject: Re: VAANZ SSIF Vaccine Platform: info [IN-CONFIDENCE:RELEASE EXTERNAL]

Kia ora Hannah,

It was great to meet you and Jonathan yesterday and thank you for sending through the information.

As requested, below is the information on the final make-up of the Vaccine Advisory Group.

Name	Position	Location	Specialisation
------	----------	----------	----------------

9(2)(ba)(i), 9(2)(b)(ii), 9(2)(j)

Pre-clinical models, regulation, commercialisation
Vaccinology
Virology, Clinical studies
Manufacturing
Vaccine science

I will review the information to date and be in touch if I require further clarification. Otherwise, we will catch-up to go over the contract variation in the next few weeks.

Ngā mihi,
Bethany

From: Hannah Walker 9(2)(a)

Date: Tuesday, 18 May 2021 at 4:18 PM

To: Bethany Andrews 9(2)(a)

Cc: Jonathan Lane 9(2)(a), Hannah Walker 9(2)(a)

Subject: VAANZ SSIF Vaccine Platform: info [IN-CONFIDENCE:RELEASE EXTERNAL]

Kia ora Bethany

Really good to meet you today – as promised attached is information discussed with Oliver.

Reporting requirements and guidelines are attached (noting that with the variation these dates will change).

Also attached is the additional information we requested from Oliver (feedback letter) that was received 3 May – we are working through what information we still need and will be in touch. The Client Report attached is the information submitted by Oliver.

Finally – Jonathan and I will set-up a meeting to discuss the contract variation, attached are the emails that confirm the variation and refer to the information needed to kick this off in the system.

Don't hesitate to get in contact if you have any questions! Jonathan will be in touch about a meeting time soon.

Aku mihi

Hannah

Hannah Walker

(She/her)

SENIOR INVESTMENT MANAGER

Strategic Investments

Science System Investment and Performance | Labour Science and Enterprise

Ministry of Business, Innovation & Employment | Te Manatū Pakihi, Aua hatanga me Ngā Kaupapa ā-Mahi

From: Jonathan Lane [\[redacted\]](#)

Sent: Tuesday, 15 December 2020 2:07 PM

To: Oliver Jarvis [\[redacted\]](#)

Cc: Hannah Walker [\[redacted\]](#)

Subject: VAANZ SSIF Vaccine Platform: Final Guidelines/Spreadsheet [IN-CONFIDENCE:RELEASE EXTERNAL]

Kia ora, Oliver. Here are the final reporting guidelines and the project-level data reporting spreadsheet. You can now start the Initial Progress Report and Forward-Looking Plan in the MBIE portal. Heike can give you a login if you don't have one.

Regards

Jonathan Lane

SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS

Science System Investment and Performance - Labour, Science and Enterprise

Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

[\[redacted\]](#)

15 Stout Street, Level 6

PO Box 1473, Wellington 6145

New Zealand

www.govt.nz - your guide to finding and using New Zealand government services

Any opinions expressed in this message are not necessarily those of the Ministry of Business, Innovation and Employment. This message and any files transmitted with it are confidential and solely for the use of the intended recipient. If you are not the intended recipient or the person responsible for delivery to the intended recipient, be advised that you have received this message in error and that any use is strictly prohibited. Please contact the sender and delete the message and any attachment from your computer.

RELEASED UNDER THE OFFICIAL INFORMATION ACT

Lisa Seng

From: Fran Priddy <fpriddy@malaghan.org.nz>
Sent: Friday, 19 March 2021 2:52 PM
To: Jonathan Lane
Cc: Hannah Walker; Oliver Jarvis
Subject: VAANZ cohort study update
Attachments: 9(2)(ba)(i)

Hi Jonathan - I hope you are well. To update you, I have not gotten a response from MOH about our revised VAANZ cohort yet. Because it is basically the same study they already approved, but with fewer people and less data collected, we are expecting a green light. I have attached a draft synopsis here so you can see how the size and objectives are modified. The clinical partners sites are revising their budgets and so we hope to have that updated information to you next week.

Kind regards,
Fran

Frances Priddy MD MPH FACP

Clinical Director
Vaccine Alliance Aotearoa New Zealand (VAANZ)
Ohu Kaupare Huaketo

9(2)(a)
E: fpriddy@malaghan.org.nz
W: www.malaghan.org.nz
A: PO Box 7060,
Wellington 6242, New Zealand



Harnessing the power
of the immune system

Attachment redacted under: 9(2)(ba)(i)

A large grey rectangular redaction box covering the content of an attachment.

Lisa Seng

From: Jonathan Lane
Sent: Tuesday, 23 March 2021 12:47 PM
To: Fran Priddy
Cc: Hannah Walker; Oliver Jarvis
Subject: RE: VAANZ cohort study update [IN-CONFIDENCE:RELEASE EXTERNAL]

Hi, Fran. Thanks for this and apologies for the late reply – I've been recovering from wisdom tooth surgery. I look forward to seeing the revised budget.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Fran Priddy [mailto:fpriddy@malaghan.org.nz]
Sent: Friday, 19 March 2021 2:52 p.m.
To: Jonathan Lane
Cc: Hannah Walker; Oliver Jarvis
Subject: VAANZ cohort study update

Hi Jonathan - I hope you are well. To update you, I have not gotten a response from MOH about our revised VAANZ cohort yet. Because it is basically the same study they already approved, but with fewer people and less data collected, we are expecting a green light. I have attached a draft synopsis here so you can see how the size and objectives are modified. The clinical partners sites are revising their budgets and so we hope to have that updated information to you next week.

Kind regards,
Fran

Frances Priddy MD MPH FACP
Clinical Director
Vaccine Alliance Aotearoa New Zealand (VAANZ)
Ohu Kaupare Huaketo

9(2)(a)

E: fpriddy@malaghan.org.nz
W: www.malaghan.org.nz
A: PO Box 7060,
Wellington 6242, New Zealand



Harnessing the power
of the immune system

Lisa Seng

From: Jonathan Lane
Sent: Wednesday, 3 March 2021 1:10 PM
To: Fran Priddy
Cc: Oliver Jarvis; Hannah Walker
Subject: RE: VAANZ cohort - MOH positive feedback [IN-CONFIDENCE:RELEASE EXTERNAL]

Great – thanks for that, Fran. Good news. I'll connect with Health.

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Fran Priddy [mailto:fpriddy@malaghan.org.nz]
Sent: Wednesday, 3 March 2021 12:20 p.m.
To: Jonathan Lane
Cc: Oliver Jarvis
Subject: Fw: VAANZ cohort - MOH positive feedback

Hi Jonathan -
We received a positive response from MOH, below.
Thanks,
Fran

From: Tim Hanlon 9(2)(a)
Sent: Wednesday, March 3, 2021 12:05 PM
To: Fran Priddy <fpriddy@malaghan.org.nz>; Janelle Duncan 9(2)(a)
Subject: RE: VAANZ cohort

Hi Fran,

Apologies for not e-mailing first thing. We had a programme workshop which took far longer than I had expected.

I did not attend Steering Group in the end as Ian Town agreed to speak to the study.

We have received the signed memo from the Director General of Health, so we can proceed as planned.

Janelle will follow up with you on the actions; it is good news!

Thank you for your patience and forbearance.

Best wishes,

Tim

Dr Tim Hanlon

Post Event Pillar Lead | COVID-19 Vaccine and Immunisation Programme
Manatū Hauora | Ministry of Health

9(2)(a) | www.health.govt.nz



From: Fran Priddy <fpriddy@malaghan.org.nz>

Sent: Wednesday, 3 March 2021 9:15 am

To: Tim Hanlon 9(2)(a); Janelle Duncan 9(2)(a)

Subject: VAANZ cohort

Hi Tim and Janelle -

I hope you are well. I am wondering if the VAANZ study was able to be considered at the meeting yesterday and any feedback?

Many thanks,

Fran

Frances Priddy MD MPH FACP

Clinical Director
Vaccine Alliance Aotearoa New Zealand (VAANZ)
Ohu Kaupare Huaketo

9(2)(a)
E: fpriddy@malaghan.org.nz
W: www.malaghan.org.nz
A: PO Box 7060,
Wellington 6242, New Zealand



Harnessing the power
of the immune system

Statement of confidentiality: This e-mail message and any accompanying attachments may contain information that is IN-CONFIDENCE and subject to legal privilege.

If you are not the intended recipient, do not read, use, disseminate, distribute or copy this message or attachments.

If you have received this message in error, please notify the sender immediately and delete this message.

This e-mail message has been scanned for Viruses and Content and cleared by the Ministry of Health's Content and Virus Filtering Gateway

Lisa Seng

From: Hannah Walker
Sent: Monday, 10 May 2021 9:34 AM
To: Oliver Jarvis; Jonathan Lane
Subject: RE: VAANZ contract [IN-CONFIDENCE:RELEASE EXTERNAL]
Attachments: 9(2)(ba)(i), 9(2)(b)(ii)

See attached Oliver.
Thanks
Hannah

From: Oliver Jarvis 9(2)(a)
Sent: Monday, 10 May 2021 9:30 AM
To: Jonathan Lane 9(2)(a)
Cc: Hannah Walker 9(2)(a)
Subject: Re: VAANZ contract

Please disregard previous email – I've realised it is in the IMS system.

Kind regards
Oliver

Oliver Jarvis

Business Development Officer / Program Manager (VAANZ)

9(2)(a)

W: www.malaghan.org.nz

A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand

PA: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Oliver Jarvis 9(2)(a)
Date: Monday, 10 May 2021 at 9:27 AM
To: Jonathan Lane 9(2)(a)
Cc: Hannah Walker 9(2)(a)
Subject: VAANZ contract

Hi Jonathan,

I'm realising we never got a copy of the countersigned original contract from MBIE. Are you able to send me a copy of this?

Kind regards
Oliver

Oliver Jarvis

Business Development Officer / Program Manager (VAANZ)

9(2)(a)

W: www.malaghan.org.nz

A: Gate 7, Victoria University, Kelburn Parade, Wellington, New Zealand

PA: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

Attachment redacted under: 9(2)(ba)(i), 9(2)(b)(ii)

Lisa Seng

From: Bethany Andrews 9(2)(a)
Sent: Wednesday, 9 June 2021 1:20 PM
To: Jonathan Lane; Hannah Walker; Neil Dalphin
Subject: VAANZ Observational Study Press Release
Attachments: MEDIA RELEASE PĀNUI PĀPĀHO New study into Pfizer-BioNTech COVID-19 vaccine to provide unique NZ data - June 2021.pdf

Bethany Andrews

GMP Manager

9(2)(a)

W: www.malaghan.org.nz

A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

New study into Pfizer-BioNTech COVID-19 vaccine to provide unique NZ data

MEDIA RELEASE | PĀNUI PĀPĀHO

10/06/2021

A clinical study getting underway in Rotorua and Christchurch will provide valuable information on how our unique population responds to the Pfizer-BioNTech COVID-19 vaccine.

The study – 'Ka Mātau, Ka Ora' (from knowledge comes wellbeing) – is being led by Vaccine Alliance Aotearoa New Zealand – Ohu Kaupare Huaketo (VAANZ) and is being undertaken to inform the national COVID-19 strategy and ultimately enhance vaccine effectiveness and confidence.

"While the Pfizer-BioNTech vaccine has demonstrated efficacy and safety in pivotal clinical trials and real-world studies, it has not yet been studied in New Zealand," says the Malaghan Institute's Dr Fran Priddy, VAANZ Clinical Director. "We want to understand how New Zealanders' immune systems respond to the vaccine, particularly in populations likely at higher risk from COVID-19, such as Māori, Pasifika and the elderly."

Dr Priddy says with vaccine safety already being closely monitored and evaluated in New Zealand and internationally, Ka Mātau, Ka Ora will focus on characterising immune responses.

"Studies done post-vaccination in other countries have shown lower antibody responses in some groups, such as the elderly and those with obesity.

"We don't know if this translates to reduced effectiveness, but it will be very hard to measure effectiveness unless we have a large outbreak. So measuring immune responses is the best proxy right now for us in New Zealand."

Dr Priddy says our 'COVID-naïve' population will also offer unique data to global research. "Vaccine immune responses may differ in populations with little prior viral exposure, as is currently the situation in New Zealand."

There are ways to increase immune responses to vaccines says Dr Priddy, so if the study identifies responses that may impact effectiveness, this could be addressed in the future by booster shots, different vaccination schedules, or different vaccine types.

Clinical Immunologist Dr Maia Brewerton, who is on the Malaghan Institute's Te Urungi Māori advisory board, says that Aotearoa is in an enviable position due to our elimination strategy and measuring specific immune markers offers a useful alternative approach to assess the vaccine response amongst our people.

"Māori and Pasifika have a greater burden of conditions like heart disease associated with more severe COVID-19 disease, however even after we account for these conditions, Māori and Pasifika are still at increased risk of developing severe disease. We know there is more to learn and this research is important to help identify and understand any differences in the immune response which can guide the optimal vaccine approach for our people," she says.

“During the influenza pandemics last century, Māori experienced higher death rates and I hope with knowledge from research like this we can prevent a repeat of this story for Māori as we journey into the uncertain future of this COVID-19 pandemic together – Ka Mātau, Ka Ora.”

Background

Ka Mātau, Ka Ora

Ka Mātau, Ka Ora (from knowledge comes wellbeing) is a clinical study to evaluate the immunogenicity of COVID-19 vaccine regimens in adults in New Zealand. It is being sponsored by the Malaghan Institute of Medical Research (as part of VAANZ) in collaboration with Pacific Clinical Research Network (PCRN), the Ministry of Health and the Human Vaccines Project.

Recruitment for Ka Mātau, Ka Ora is being undertaken at two PCRN study sites –Lakeland Clinical Trials in Rotorua and Southern Clinical Trials in Christchurch. The study aims to enrol at least 300 adult participants with a focus on Māori, Pasifika, older adults ≥65 years old, and those with co-morbidities associated with increased risk of COVID-19. The study will assess immune responses for up to 12 months after the last vaccine dose.

Anyone interested in getting involved in the study can contact:

Lakeland Clinical Trials | 07 347 7870| info@lakelandtrials.com | lakelandtrials.com
Southern Clinical trials | 0800 358788 | enquiries@sctrials.co.nz | sctrials.co.nz

Vaccine Alliance Aotearoa New Zealand – Ohu Kaupare Huaketo (VAANZ)

VAANZ is a partnership between the Malaghan Institute of Medical Research, the University of Otago and Victoria University of Wellington. As part of the Government’s COVID-19 vaccine strategy, VAANZ is running a national COVID-19 vaccine evaluation and development platform to support the development of potential domestic and international second generation COVID-19 vaccines, focusing on vaccines that provide longer immunity, are effective against emerging coronavirus strains and could be manufactured domestically in the future. VAANZ is also helping build New Zealand’s capability in vaccine development and production to ensure New Zealand is prepared for future pandemics.

www.malaghan.org.nz/infectious-diseases/covid-19/

Pacific Clinical Research Network (PCRN)

PCRN is a research network of clinical trial facilities attached to or part of general practice. The founding partners of the network are the Southern Clinical Trials group and Lakeland Clinical Trials Group in New Zealand and Paratus in Australia. PCRN has driven the evolution of clinical trial facilities in New Zealand over 20 years and is now the largest clinical trial network in New Zealand.

Media enquiries

Gail Marshall (Head of Communications, Malaghan Institute of Medical Research)
gmarshall@malaghan.org.nz | +64 21 360 432

www.malaghan.org.nz

Lisa Seng

From: Jonathan Lane
Sent: Wednesday, 9 June 2021 3:01 PM
To: Bethany Andrews; gmarshall@malaghan.org.nz
Subject: RE: VAANZ Observational Study Press Release

Thanks, Bethany and Gail. Looks good and I understand Hilary Morrison from MBIE has gone back to Gail to that effect.

Regards

Jonathan Lane (he/him)
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand

From: Bethany Andrews 9(2)(a)
Sent: Wednesday, 9 June 2021 1:20 pm
To: Jonathan Lane 9(2)(a); Hannah Walker 9(2)(a); Neil Dalphin 9(2)(a)
Subject: VAANZ Observational Study Press Release

Bethany Andrews
GMP Manager

9(2)(a)

W: www.malaghan.org.nz
A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

Lisa Seng

From: Fran Priddy <fpriddy@malaghan.org.nz>
Sent: Thursday, 24 June 2021 5:13 PM
To: Shayma Faircloth; David Murdoch; Tim Hanlon; Maia Brewerton; Jonathan Lane; Brittany Lewer
Cc: Peter McIntyre
Subject: Re: VAANZ Research Oversight Committee (CV-ROC) Meeting 1: Ka Mātau, Ka Ora
Attachments: 9(2)(ba)(i)

Dear Shayma and all -
Attached is a PDF of the study update I will share at the meeting tomorrow.
Kind regards,
Fran

Frances Priddy MD MPH FACP
Clinical Director
Vaccine Alliance Aotearoa New Zealand (VAANZ)
Ohu Kaupare Huaketo

9(2)(a)
E: fpriddy@malaghan.org.nz
W: www.malaghan.org.nz
A: PO Box 7060,
Wellington 6242, New Zealand



Harnessing the power
of the immune system

From: Shayma Faircloth 9(2)(a)
Sent: Monday, June 21, 2021 10:52 AM
To: David Murdoch <david.murdoch@otago.ac.nz>; Tim Hanlon 9(2)(a); Maia Brewerton 9(2)(a); Jonathan Lane 9(2)(a); Fran Priddy <fpriddy@malaghan.org.nz>; Brittany Lewer 9(2)(a)
Cc: Peter McIntyre <peter.mcintyre@otago.ac.nz>
Subject: RE: VAANZ Research Oversight Committee (CV-ROC) Meeting 1: Ka Mātau, Ka Ora

Dear all,

Please find attached the agenda for the meeting on Friday. I also attach the protocol and relevant documents for the VAANZ study for your records.

Kind regards,
Shayma

Shayma Faircloth | [She/Her](#)
Senior Advisor, Post Event Workstream | COVID-19 Vaccine and Immunisation Programme
Manatū Hauora | Ministry of Health

9(2)(a) | www.health.govt.nz

-----Original Appointment-----

From: Shayma Faircloth

Sent: Thursday, 17 June 2021 11:23 am

To: Shayma Faircloth; David Murdoch; Tim Hanlon; Maia Brewerton (ADHB); Jonathan Lane; Fran Priddy; Brittany Lower

Subject: VAANZ Research Oversight Committee (CV-ROC) Meeting 1: Ka Matau, Ka Ora

When: Friday, 25 June 2021 8:30 am-9:30 am (UTC+12:00) Auckland, Wellington.

Where: ROOM WLG 45.6 (4); Microsoft Teams Meeting

Dear all,

Thank you for your contribution to the doodle poll. The first meeting will take place on Friday 25 June 8:30AM.

We will be in touch with an agenda shortly.

Kind regards,

Shayma

Secretariat for CV-ROC

Microsoft Teams meeting

Join on your computer or mobile app

[Click here to join the meeting](#)

9(2)(a)




[Learn More](#) | [Meeting options](#)

Statement of confidentiality: This e-mail message and any accompanying attachments may contain information that is IN-CONFIDENCE and subject to legal privilege.

If you are not the intended recipient, do not read, use, disseminate, distribute or copy this message or attachments.

If you have received this message in error, please notify the sender immediately and delete this message.

Attachment redacted under: 9(2)(ba)(i)



RELEASED UNDER THE
OFFICIAL INFORMATION ACT

Lisa Seng

From: Graham LeGros <glegros@malaghan.org.nz>
Sent: Monday, 22 March 2021 7:05 AM
To: Peter Crabtree; Simon Rae; Jonathan Lane
Cc: Oliver Jarvis
Subject: Update on the report that SARS-CoV-2 South African variants infection of mice
Attachments: The B.1.351 and P.1 variants extend SARS-CoV-2 host range to mice[1][1].pdf

Follow Up Flag: Follow up
Flag Status: Completed

Dear All,

No doubt you are aware of the recent Biorix paper indicating that the variants of COVID-19 are able to infect mice raising the issue of future evolution of the virus and animal reservoirs for later pandemics.

We have been aware of this for a while.

- 1) As we speak the validity of the paper is being checked out (by our VAANZ scientist at NIAID) and we will know in 2 weeks if the reported results can be reproduced

It has happened before... In the 1950s, the human coronavirus OC43 began to diverge into its present genotypes.^[89] Phylogenetically, mouse hepatitis virus (*Murine coronavirus*), which infects the mouse's liver and central nervous system,^[90] is related to human coronavirus OC43 and bovine coronavirus. Human coronavirus HKU1, like the aforementioned viruses, also has its origins in rodents.^[75] We

- 2) the good news to always keep in mind is that the immunity generated by vaccine should be able to protect against these strains as they all require that RBD structure to gain entry to cells. So good high titre neutralisation antibody is where we need to aim.
- 3) It has already been reported for zoo cats etc.
- 4) The mouse adapted virus strains which have been produced to date do not infect human cells nearly as well.

Happy to discuss if needed. How or when media pick this up is decision for Ian Town and Ministry of Health I suppose. Ian knows.

G

Prof. Graham Le Gros CNZM FRSNZ FRCPA (Hon)
Director of Research

9(2)(a)

E: director@malaghan.org.nz

O: <http://orcid.org/0000-0002-5721-0442>

A: PO Box 7060, Wellington 6242, New Zealand

W: www.malaghan.org.nz



Harnessing the power
of the immune system

Lisa Seng

From: Oliver Jarvis 9(2)(a)
Sent: Friday, 12 February 2021 4:07 PM
To: Jonathan Lane; Hannah Walker
Cc: Fran Priddy; James Ussher; Graham LeGros
Subject: Vaccine Rollout Trial
Attachments: 9(2)(ba)(i), 9(2)(b)(ii)

Follow Up Flag: Follow up
Flag Status: Completed

Hi Jonathan & Hannah,

Attached is the 2/3 pager on the trial discussed yesterday.

As mentioned, the sooner we hear back the better, as there is real time pressure for this, especially given today's announcement.

Kind regards
Oliver

Oliver Jarvis
Program Manager
Vaccine Alliance Aotearoa New Zealand
Ohu Kaupare Huaketo

9(2)(a)
[Redacted]
[Redacted]

W: www.malaghan.org.nz
A: PO Box 7060, Wellington 6242, New Zealand



Harnessing the power
of the immune system

Attachement redacted under: 9(2)(ba)(i), 9(2)(b)(ii)
[Redacted]

Lisa Seng

From: Jonathan Lane
Sent: Friday, 9 April 2021 12:55 PM
To: Graham Le Gros (glegros@malaghan.org.nz); Oliver Jarvis
9(2)(a)
Subject: We expect decision Tuesday 13 April [IN-CONFIDENCE:RELEASE EXTERNAL]

Regards

Jonathan Lane
SENIOR INVESTMENT MANAGER, STRATEGIC INVESTMENTS
Science System Investment and Performance · Labour, Science and Enterprise
Ministry of Business, Innovation & Employment / Hīkina Whakatutuki

9(2)(a)

15 Stout Street, Level 6
PO Box 1473, Wellington 6145
New Zealand